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Abstract 
Efavirenz displays many desirable pharmacokinetic properties such as a long 
half-life allowing once daily dosing and potency against HIV. Despite these 
favourable properties efavirenz-containing therapy is associated with the 
development of central nervous system (CNS) toxicities. Current investigations 
indicate that high plasma concentrations of efavirenz play a putative role in the 
development of CNS side effects, but there is a current paucity of data relating to 
the underlying mechanisms of toxicity. Various nanotechnologies have been 
explored in attempts to mitigate some of the limitations with efavirenz. While 
there has been progress in increasing the bioavailability of efavirenz there has 
been no attempt to assess the impact of increased exposure to efavirenz on CNS 
toxicity. The body of work presented in this thesis aimed firstly to investigate the 
underlying mechanism of efavirenz CNS toxicity and secondly to assess uptake 
and CNS toxicity of efavirenz and a novel solid drug nanoformulation (SDN) of 
efavirenz. 
The work presented in this thesis utilised a variety of in vitro, in vivo and in 
silico methodologies. Chapter 2 utilised allelic discrimination polymerase chain 
reaction in order to investigate the association of single nucleotide polymorphism 
(SNPs) in the gamma aminobutyric acid receptor with early treatment 
discontinuation of efavirenz. In order to assess the effects of SDN efavirenz on 
the occurrence of CNS toxicities, an in vivo model of anxiety (elevated plus 
maze) was employed (chapter 3). Chapter 4 detailed the development of a robust 
and sensitive liquid chromatography tandem mass spectrometer assay for the 
detection of efavirenz in multiple matrices. The uptake of efavirenz and SDN 
efavirenz in the CNS was investigated utilising cellular uptake and inhibition 
studies (chapter 5). Physiologically based pharmacokinetic (PBPK) simulations 
were used to investigate the distribution of efavirenz in plasma, cerebrospinal 
fluid (CSF) and brain tissue (chapter 6).  
Despite an initial trend with Rs211014 and Rs6556547 (univariate analysis) of 
the training cohort, these SNPs were not found to be significant in the 
multivariate analysis or in either analysis of the test cohort. Following multiple 
doses rats treated with efavirenz, but not SDN efavirenz, exhibited anxiety-like 
behaviour in the EPM. The profile of changes indicated some clear behavioural 
effects that are likely to be linked to drug-related CNS effects. In particular, a 
tendency of efavirenz to increase time spent on the central platform may be 
indicative of anxiogenesis. Cellular accumulation of efavirenz was reduced 
significantly by montelukast and amantadine, with the reduction in accumulation 
by prazosin bordering on significance (indicating efavirenz may be a substrate 
for OCT1 and an SLCO transporter). Additionally, cellular accumulation of SDN 
efavirenz particles was reduced by dynasore, indicating dynamin-mediated 
uptake. PBPK simulations predicted efavirenz accumulation in brain tissue, with 
a tissue to plasma ratio 15.8. 
The natural occurrence of conditions such as depression involves a complex 
interplay of factors influencing neurotransmission. This makes identifying single 
predictors of efavirenz CNS toxicity more difficult. The data presented in this 
thesis may be built upon to understand the mechanisms governing efavirenz 
disposition in the CNS and factors influencing the occurrence of CNS toxicity.
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1.1 Human Immunodeficiency Virus 
The human immunodeficiency virus (HIV) pandemic has been a global issue for 
over 30 years; at the end of 2013, 35 million people were estimated (by the 
World Health Organisation [WHO]) to be HIV positive worldwide with 
approximately 2.1 million new infections and 1.5 million deaths reported (1). 
Although organisations such as the United Nations Programme on HIV/AIDS 
(UNAIDS) show a declining trend in HIV infection (50% decline in the number 
of HIV infections in 26 countries between 2002 and 2012), HIV still represents a 
significant global health burden (2). 
 
1.2 Replication Cycle of HIV 
HIV infection is characterised by infection and subsequent depletion of CD4+ T 
cells (3). The CD4+ T cells play a crucial role in the adaptive immune response to 
exogenous pathogens (4). Antigen presenting cells, such as dendritic cells, 
interact with naïve CD4+ T cells leading to cellular proliferation and 
differentiation into CD4+ subsets (5). The differentiated effector cells are 
involved in multiple aspects of immune response, including elimination of 
extracellular and intracellular pathogens, mediation of humoral immune 
response, recognition of self and foreign antigens (5). The loss of CD4+ T cells 
has a dramatic impact on the host immune system, rendering the host vulnerable 
to opportunistic infections, such as tuberculosis and other bacterial and fungal 
infections (6). The following sections will discuss the progression of viral 
infection including attachment, fusion, reverse transcription, integration, 
 4 
transcription, ribonucleic acid (RNA) export, assembly and finally release of 
mature virions. 
 
1.2.1 Viral Attachment 
Following the introduction of HIV to the host system, the first stage of the viral 
lifecycle is attachment of the virion to the host cell (Figure 1). Most frequently, 
HIV recognises and binds to the CD4 glycoprotein (gp) and co-receptors C-C 
chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4) via a 
trimeric envelope glycoprotein (env), with each subunit formed from an exterior 
(gp120) and a transmembrane (gp41) region (7). However, CD4 is not the only 
means of viral attachment. CD4 independent attachment has been demonstrated 
in monocyte-derived dendritic cells via gp120 binding to a number of C-type 
lectin receptors (8).  
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1.2.2 Fusion 
Following attachment, the virus enters the host cell via membrane fusion. 
Binding of gp120 to CD4 and co-receptor (either CCR5 or CXCR4 are engaged, 
dependent on viral tropism) induces a series of conformational changes in the 
env protein leading to the exposure of the core gp41 N-terminal fusion peptide 
(10). The resulting interaction induces fusion between the viral capsid cell 
membrane followed by infection of the host cell (7, 11).  
 
Following viral entry to the host cell the process of uncoating occurs to release 
the contents of the viral capsid into the cellular cytoplasm (12). The core of the 
HIV virion consists of the viral genome and associated proteins, including gag 
(proteolytically cleaved to produce matrix, capsid, nucleocapsid and p6 proteins), 
pol (proteolytically cleaved to produce the reverse transcriptase [RT], integrase 
[IN] and protease [PR]) and env contained within a conical capsid (12, 13).  
 
1.2.3 Reverse transcription 
As a retrovirus, the genome of HIV is RNA and requires transcription to double-
stranded deoxyribonucleic acid (DNA) prior to integration into the host genome. 
DNA is produced via reverse transcription, accomplished by the enzyme RT 
(14). Initiation of reverse transcription is achieved by annealing of host transfer 
RNA (tRNA) to viral RNA. This complex is recognised by RT and reverse 
transcription may commence via elongation of the 3′ end of the tRNA/RNA 
complex. As the DNA is transcribed to form a RNA/DNA hybrid, the RNA is 
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degraded via RNase activity of RT producing newly synthesised DNA (15). The 
production of DNA via RT is highly error prone due to the lack of exonucleolytic 
proofreading, leading to a high error rate of 1/1700 and in certain mutational 
hotspots 1/70 (16). This lack of fidelity can lead to the emergence of HIV strains 
capable of drug resistance and immune escape (17). 
 
1.2.4 Integration 
The next stage in the viral life cycle is integration of the viral DNA with the host 
DNA. The newly synthesised viral DNA forms a stable complex with the IN 
enzyme that is transported to the nucleus. The DNA is then processed for 
integration. Two nucleotides are first removed from 3′ ends of the viral DNA. 
The free 3′ ends are now able to "attack" phosphodiester bonds in the host DNA, 
resulting in covalent linkage between the 3′ end of the viral DNA and the 5′ end 
of the host DNA. The remaining viral 5′ ends are repaired via host enzymes 
resulting in complete integration of the viral DNA (18). 
 
1.2.5 Transcription 
The transcription of new viral RNA is produced by partial subversion of host 
enzymes. Transcription is initiated by host RNA polymerase II but full 
transcription is not possible, resulting in short viral transcripts (19). To 
circumvent this limitation, HIV transcription is facilitated by transactivator of 
transcription (TAT). The binding of TAT to transactivation responsive element 
(TAR) and the recruitment of positive transcription elongation factor b lead to ~ 
  8 
100-fold increase in the production of viral RNA, primarily via enhancement of 
transcription elongation (13, 20, 21). 
 
1.2.6 RNA Export 
Transcription yields both spliced and unspliced messenger RNA (mRNA), 
resulting in more than 40 different splice products. Eukaryotic cells typically 
degrade unspliced and incompletely spliced mRNA in the nucleus (22, 23). 
Completely spliced mRNA (1.8kb mRNA coding for TAT, REV and Nef) is 
transported by endogenous transport mechanisms. Unspliced and incompletely 
spliced mRNA (9kb and 4kb mRNA coding for gag, pol and env) require the 
viral protein REV for transport to the cytoplasm (22). Bound REV is able to 
interact with chromosome region maintenance 1 (also known as exportin 1) in 
the presence of guanosine-5'-triphosphate (GTP), in the form of Ran GTPase (22, 
23). The complex is transported to the cytoplasm, via nuclear pore complexes, 
where hydrolysis of GTP leads to instability of the complex and the release of 
viral mRNA to the cytoplasm where translation can occur. Rev is then 
transported back to the nucleus via importin β (22). 
 
1.2.7 Assembly and Release 
The process of assembly occurs at the plasma membrane (in the majority of 
cells), where key viral components (including the RNA genome, env, RT and 
PR) are packaged into immature virions (24). As with many viral processes, 
packaging relies on both viral proteins and the subversion of host systems. The 
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various processes involved in packaging (including creation of spherical viral 
particles, concentration of env and packaging of RNA) are mediated by Gag-Pro-
Pol. Although Gag-Pro-Pol is able to assemble the virions, release is 
accomplished via host endosomal sorting complexes required for transport (25). 
Viral maturation begins simultaneously with release of the virions, beginning 
with proteolytic cleavage of Gag-Pro-Pol via PR. Maturation continues with the 
products of Gag-Pro-Pol rearranging to form mature viral particles (25). 
 
1.3 Current Antiretroviral Therapy: Mechanisms of Action  
Over the past 30 years there have been remarkable advances in HIV therapy. 
Treatment has evolved from simple monotherapy to a complex regimen 
comprised of multiple drugs from numerous classes. Currently, the US Food and 
Drug Administration (FDA) has approved 27 drugs for the treatment of HIV, 
which include 9 nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), 5 
non-nucleoside reverse transcriptase inhibitors (NNRTI), 9 protease inhibitors 
(PI), 1 fusion inhibitor, 1 chemokine receptor antagonist and 2 IN inhibitors 
(Figure 2) (26). As of 2013, of these 7 are recommended by the WHO for 
treatment of antiretroviral-naïve patients (Table 1) (27). As previously discussed, 
HIV is highly error prone (17), enabling the virus to quickly adapt to 
antiretroviral agents through acquisition and selection of resistance mutations via 
a similar general mechanism to that of cytotoxic T-lymphocytes (CTL) escape 
(17, 28). Resistance to monotherapy arises extremely quickly and so effective 
therapy requires at least three drugs in combination to simultaneous target 
multiple viral targets (29). Through prolonged viral suppression and increased 
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CD4+ T-cell counts, modern antiretroviral therapy has improved patient survival 
and transformed HIV into a manageable but chronic infection.  
 
 
Figure 2. The graph above shows the number of FDA approved antiretrovirals and the year of 
approval. Also highlighted are the first in class antiretrovirals zidovudine (AZT NRTI), 
saquinavir (SQV PI), nevirapine (NNRTI NVP), enfuvirtide (entry inhibitor T-20) maraviroc 
(entry inhibitor MRV) and raltegravir (integrase inhibitor RAL). Data extracted from (26). 
 
 
 
 
 
  11 
 NNRTI or boosted PI NRTI Backbone 
First Line Therapy Efavirenz (NNRTI) Tenofovir 
Emtricitabine 
Alternative 
Efavirenz (NNRTI) 
Zidovudine 
Emtricitabine 
 Nevirapine (NNRTI) Zidovudine 
Emtricitabine 
 Nevirapine (NNRTI) Tenofovir 
Emtricitabine 
Second Line Therapy 
Atazanavir (PI) 
Ritonavir (PI) 
Tenofovir 
Emtricitabine 
Alternative Lopinavir (PI) 
Ritonavir (PI) 
Tenofovir 
Emtricitabine 
 
Table 1. The table above shows the World Health Organisations current recommendations for 
antiretroviral therapy. First line therapy consists of a NNRTI supported by a NRTI backbone. 
When this option is unsuitable (due to viral rebound or patient toxicity), second line therapy 
consists of a PI (boosted by ritonavir) supported by a NRTI backbone (27).  
 
1.3.1 Nucleoside Reverse Transcriptase Inhibitors 
The enzyme RT catalyses a key step in the HIV life cycle.  As shown in Figure 1, 
reverse transcriptase translates the viral genome from RNA to DNA. The NRTI 
class of antiretroviral drugs (e.g. zidovudine, tenofovir disoproxil fumarate and 
emtricitabine) are analogues of endogenous nucleosides with one significant 
difference (30). Endogenous nucleosides are incorporated into DNA via 
phosphodiester bonds. NRTIs are incorporated into the viral DNA however; they 
are incapable of binding to other nucleosides. NRTIs lack a hydroxyl group at 
the 3′ position, this is essential for the incorporation of further nucleosides (31). 
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The incorporation of an NRTI prevents further synthesis of the DNA chain, 
leading to non-functional DNA that cannot be incorporated into the host DNA. 
 
1.3.2 Non-Nucleoside Reverse Transcriptase Inhibitors 
NNRTI’s act on the same viral target as NRTI’s but the mechanism of action is 
significantly different. NNRTI’s inhibit reverse transcriptase via allosteric 
modulation, acting via non-competitive inhibition. Binding of NNRTI’s to a 
hydrophobic pocket (approximately 10Å from the active site) induces the side 
chains of tyrosine 181 and 188 in the active site of reverse transcriptase to invert 
orientation. This conformational change leads to a decrease in the binding 
affinity of endogenous nucleosides, disrupting reverse transcription (14). Due to 
the different mechanisms of action, NNRTI’s can be used in conjunction with 
NRTI’s acting synergistically. Currently there are 5 NNRTIs available 
(efavirenz, nevirapine, delavirdine, rilpivirine and etravirine). The work 
presented in this thesis focuses on efavirenz and a novel nanoformulation of 
efavirenz, discussed in section 1.4.1 and 1.5.3, respectively.  
 
1.3.3 Protease Inhibitors 
The viral enzyme PR is responsible for the proteolytic cleavage of the Gag-Pol 
polyprotein to produce functional viral proteins (32). Inhibition of this process 
(via PI's, such as lopinavir, atazanavir and darunavir) leads to incomplete viral 
maturation resulting in the formation of incomplete, non-infectious virions (32, 
33). Viral PR targets phenylalanine-proline and tyrosine-proline bonds found in 
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Gag-Pol. As host protease does not usually target these bonds, PIs are able to 
target the viral PR active site whilst minimising activity against host proteases 
(34). The prescription of PI's supported by an NRTI backbone may be 
recommended as an alternative when NNRTIs are unsuitable (e.g. due to viral 
resistance or patient intolerance).  
 
1.3.4 Integrase Inhibitors 
Following the production of viral DNA, the viral genome is fused into the host 
DNA via the viral enzyme IN. The first stage of this process is the formation of 
an IN-viral DNA complex. Following complex formation the 3′ end of the viral 
DNA is processed, producing reactive hydroxyl groups. The complex is 
transported to the host cell nucleus (35). This complex then targets host DNA, 
where the reactive 3′ hydroxyl groups attack the phosphodiester bond and are 
covalently linked to the host DNA. This is followed by full integration of the 
viral genome as host repair mechanisms integrate the viral DNA (35, 36). 
Inhibitors of IN (such as dolutegravir, elvitegravir and raltegravir) act via 
competitive antagonism of the IN active site, via chelation of the divalent metals 
of the IN active site (35). By preventing the binding of the IN-viral DNA 
complex to the host DNA, IN inhibitors prevent the incorporation of the viral 
genome halting the viral life cycle (36). 
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1.3.5 Entry Inhibitors 
All the previously discussed classes of antiretroviral drugs act by ceasing the 
propagation of the virus within cells that are already infected by HIV. Entry 
inhibitors aim to prevent the virus from penetrating the cell, thus preventing the 
infection of new cells. There are a number of strategies currently at various 
stages of development (e.g. ibalizumab, a monoclonal antibody that targets CD4 
is currently in phase II). However, there are only 2 drugs currently approved by 
the FDA, maraviroc and enfuvirtide (also known as T20) (37-39). 
 
In order for cell entry to take place, the virus must bind to CD4 receptor and a 
coreceptor. A polymorphism in CCR5 (CCR5-Δ32) leads to the production of a 
non-functional protein and has been shown to confer resistance to HIV infection 
and disease progression (40), but carriers are otherwise healthy. This was the 
basis for development of CCR5 inhibitors and the first in class, maraviroc, 
prevents viral entry via inhibition of the coreceptor CCR5 (41). Limitations of 
maraviroc include poor and variable pharmacokinetics and the necessity for viral 
tropism tests prior to initiation of therapy. Only HIV that utilises CCR5 is 
inhibited by maraviroc, which has no effect on HIV that utilises CXCR4 as a co-
receptor (39, 42).  
 
Another approach to preventing viral entry is to inhibit fusion of the viral capsid 
with the cell membrane. Enfuvirtide is a synthetic peptide that binds to gp41 
preventing it from interacting with the cell membrane and halting fusion (39). As 
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enfuvirtide is a peptide, oral administration is problematic. The presence of 
peptidases in the GI rapidly degrades enfuvirtide resulting in very poor 
bioavailability, thus parenteral administration is required to bypass the GI.(43). 
Given the high dosing frequency (twice daily) and the route of administration 
(subcutaneous [SC]), prescription of enfuvirtide is usually reserved for when 
other therapeutics have failed (44). Recent studies have sought to address this 
issue via a polylactic-co-glycolic acid microparticle formulation to provide 
sustained release (sustained in vitro release over 18 days) (44).  
 
1.4 The Central Nervous System in HIV 
The central nervous system (CNS) is a key anatomical region in HIV therapy as 
the CNS is separated from systemic circulation by the blood brain barrier (BBB) 
(45). The BBB is comprised of a complex interplay of multiple cell types that 
produce an effective barrier limiting the entry of both endogenous and exogenous 
molecules (Figure 3). The BBB is characterised by the presence of tight cellular 
junctions, formed by interactions between key proteins (including claudins, 
occludin and junction adhesion molecule) expressed by the endothelial cells of 
the BBB (46, 47). Endothelial cells are supported by a number of other cells, 
providing processes necessary for the formation of the BBB, capillary basement 
membrane, astrocyte foot processes and pericytes (46). 
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In addition to the presence of tight junctions, limiting paracellular diffusion, 
endothelial cells highly express metabolising enzymes, efflux transporters and 
possess a large amount of mitochondria (required for active transport and 
metabolism), all of which limit access of antiretrovirals to the CNS (49, 50). 
Understanding the mechanisms the BBB employs to defend the CNS enables 
identification of physicochemical properties effecting CNS penetration.  
 
Molecular weight has been identified as a key factor determining BBB 
penetration. Low molecular weight chemicals have been shown to more readily 
pass the BBB than those with a higher molecular weight. According to Lipinski’s 
“rule of five” (Table 2) the molecular weight cut off for good permeability is 
≤500 KDa. However, for BBB penetration it has been suggested an even lower 
molecular weight needs to be applied (≤ 400 KDa) (51, 52). The lipophilicity of a 
compound has also been shown to play a significant role in BBB penetration, 
with an oil/water distribution (LogP) of ≤5 indicating good permeability. In 
addition to the physicochemical properties, there are a number of 
pharmacological considerations that may affect BBB permeability. Highly 
protein bound antiretrovirals are unlikely to readily pass the BBB as only the free 
drug is available for permeation. The endothelial cells of the BBB have been 
shown to express many cytochrome P450 (CYP) enzymes (both CYP2B6 and 
CYP3A4 mRNA were expressed in primary brain endothelial cultures) and drug 
transporters (e.g P-glycoprotein [P-gp] and breast cancer resistance protein 
[BCRP]) (47, 53). The expression of metabolic enzymes and drug transporters 
provide an effective barrier to antiretroviral penetration across the BBB. 
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Physicochemical 
Property 
Value for good 
permeability 
Value for good 
BBB permeability 
Number of Hydrogen Bond 
Donors 
≤ 5 ≤ 5 
Number of Hydrogen Bond 
Acceptors 
≤ 10 ≤ 5 
Molecular Weight ≤ 500 ≤ 400 
Log P ≤ 5 1.5-2.7 
Number of Rotatable 
Bonds 
≤ 10 ≤ 5 
 
Table 2. Lipinski’s rule of 5 shows the desired physicochemical properties of orally available to 
predict good absorption or permeability across a biological membrane and specifically the BBB. 
These rules only apply to drugs utilising passive permeation. Permeability of transporter proteins 
substrates is dependant of the type of transporter (influx or efflux), affinity and abundance of the 
transporter. Data extracted from (51, 52) 
 
The BBB is highly effective at preventing the penetration of many antiretrovirals 
into the CNS. Using current technology CNS penetration is assessed using 
cerebrospinal fluid (CSF) as a surrogate marker. However, it is currently being 
debated as to how accurate a marker CSF concentrations are for brain 
concentrations when determining drug exposure (54-56). It has been 
demonstrated in guinea pigs that brain tissue concentrations of nevirapine not 
only differ from those in the CSF but also vary between brain regions (54). 
Nevirapine uptake was shown to be 0.32 ml/g in the CSF whereas nevirapine 
uptake was lower in the choroid plexus (0.25 ml/g) and higher in the pituitary 
(1.61 ml/g) when compared to the CSF (54) . These data indicate that predicting 
brain tissue concentrations from CSF is problematic. Indeed, concentrations 
within CSF have been shown to vary depending on where the sample was taken. 
Lamivudine (a nucleoside reverse transcriptase inhibitor) has been shown to be 
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5-fold higher in CSF sampled from the lumbar region compared to ventricular 
CSF in rhesus monkeys (55).  
 
Antiretrovirals display wide variation in CSF penetration (considered by CSF 
sampling). For example CSF concentrations of efavirenz, nevirapine and 
lopinavir were determined to be lower than plasma concentrations, 0.5%, 63% 
and 0.23%, respectively (57-59). Despite lower concentrations in the CSF, 
antiretroviral concentrations maybe sufficient to display antiretroviral activity, 
exceeding the concentration producing 50% inhibition (IC50) (57, 59). However, 
this is not always the case and tenofovir CSF concentrations were shown to be 
5% of plasma concentrations with 77% of patients (cohort of 183 patients) 
having CSF concentrations below the IC50 (60). 
 
A significant limitation of current antiretroviral treatment is that while the BBB 
limits the penetration of many antiretrovirals, HIV is able to infect the CNS and 
replicate (47). HIV crosses the BBB via infected peripheral blood lymphocytes 
and monocytes, which migrate to the brain (61, 62). Although the mechanism of 
HIV passage across the BBB has not been fully elucidated, it has been 
demonstrated that infection of CD14+ and CD16+ monocytes results in an 
increase in migration across to the brain in response to CCL2 (a chemoattractant) 
when compared to uninfected cells (62). It is postulated that continued viral 
replication in the CNS is a contributor to viral rebound. Currently, HIV is 
incurable and upon termination of therapy the virus is able to re-infect biological 
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compartments previously showing suppression of viral growth (63). A further 
concern is the development of resistant strains of HIV.  
 
In addition to the risk of viral rebound, viral replication in the CNS can lead to 
the development of HIV-associated neurocognitive disorder (HAND). Once 
released, HIV is able to infect brain parenchyma triggering a signalling cascade 
resulting in increased concentrations of neurotoxins (61). The increase in 
neurotoxins eventually leads to neuronal damage and cognitive impairment. 
HAND can be subdivided into asymptomatic neurocognitive impairment, mild 
neurocognitive disorder and HIV-associated dementia. Symptoms present in a 
range of psychological disturbances (including sleep disorders, depression and 
mania) (61).  
 
1.4.1 Efavirenz Associated Central Nervous System Side Effects 
Currently the WHO recommends global treatment of HIV should consist of 1 
NNRTI supported by an NRTI backbone (64). The most frequent combination 
administered is efavirenz combined with tenofovir and emtricitabine. This 
combination is co-formulated into a single tablet administered once daily 
(Atripla) (26).  
 
Patients receiving efavirenz-containing therapy frequently report CNS 
disturbances. Symptoms occur with a high frequency and can include depression, 
anxiety, abnormal dreams and hallucinations (65). The majority of patients report 
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development of CNS disorders shortly after commencing efavirenz with 
symptoms dissipating during the initial months of therapy. A minority of patients 
continue to experience symptoms for the duration of receiving efavirenz-
containing therapy (66). More recently however, efavirenz CNS toxicities have 
been shown to have more long-term effects. Leutscher et al demonstrated a 60% 
discontinuation rate of efavirenz versus 3% receiving non-efavirenz-containing 
therapy. It was further shown that half of the patients discontinuing efavirenz did 
so ≥ 12 months (67). 
 
In addition to the negative impact on the quality of the patient’s life, CNS 
toxicities may also lead to a decrease in patient adherence. Poor patient 
adherence to antiretroviral medication is a major concern with regards to HIV 
therapy but in particular efavirenz therapy. Exposure to sub-therapeutic 
concentrations can lead to therapeutic failure and the development of viral 
mutations and resistant strains of HIV (sometimes class-resistant). NNRTI’s are 
considered to have a low genetic barrier to the development of resistance; a 
single mutation (such as K103N) can confer resistance to multiple NNRTI’s (68). 
The impact of CNS side effects on patient adherence is not clearly defined. 
Previous studies imply patients demonstrate tolerance to CNS side effects, 
resulting in little or no impact on patient adherence (69, 70).  
 
Many studies have attempted to elucidate the relationship between CNS adverse 
effects and variability in plasma concentrations of efavirenz. Efavirenz is 
metabolised primarily by CYP2B6 and to a lesser extent CYP2A6, CYP3A4 and 
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uridine 5'-diphospho-glucuronosyltransferase isoform 2B7 (UGT2B7) (71). 
Higher plasma concentrations of efavirenz have been shown to be associated 
with polymorphisms in these enzymes, in particular polymorphisms in CYP2B6, 
such as 516G>T, CYP2B6*6 (constituted by 516G>T and 785A>G 
polymorphisms) and CYP2B6*16 (containing 983T>C and the 785A>G 
polymorphisms) (72, 73). 
 
The relationship between patient polymorphisms and plasma concentrations of 
efavirenz has been clearly demonstrated. However, the association of higher 
pharmacokinetic exposure to efavirenz and CNS toxicities remains unclear. 
Polymorphisms in CYP2B6 have been shown to be associated with increased 
incidence of CNS side effects in some studies. Marzolini et al reported plasma 
concentrations of >4000 µg/l are associated with a 3-fold increase in CNS side 
effects (Figure 4) (74). Conversely; Haas et al described a higher frequency of 
the CYP2B6 516G>T polymorphism in African-Americans than European-
Americans but no significant difference in the occurrence of neuropsychiatric 
adverse effects, while Takahashi et al concluded that there was no correlation 
with efavirenz plasma concentrations and CNS side effects in Japanese patients 
(75, 76). Our current understanding leads to the conclusion that increased plasma 
concentrations of efavirenz play a putative role in the development of CNS side 
effects, but there is a current paucity of data relating to the underlying 
mechanisms of toxicity.  
  23 
 
Figure 4. The graph above shows the association with probability of either viral suppression 
(solid line) or occurrence of CNS toxicity (broken line) with concentration of efavienz. The 
optimal range highlights efavirenz concentrations of 1000 µg/l and 4000 µg/l where viral 
suppression is maintained with acceptable occurrence of CNS toxicity. Figure source (74). 
 
1.5 Limitations of Current Antiretroviral Therapeutics 
Currently all licensed antiretroviral drugs (except enfuvirtide) are prescribed as 
solid formulations for oral administration. The pharmacokinetics of orally 
administered drugs are subject to the first pass effect, poor absorption and the 
hostile environment of the gastrointestinal (GI) tract (77). Before reaching the 
site of action, antiretroviral drugs have to first enter the GI tract and be absorbed. 
The extreme pH environment and the presence of digestive enzymes degrade 
some drugs prior to absorption. Bioavailability is also influenced by poor 
solubility and the presence of drug transporters in enterocytes of the GI tract 
(78). Following absorption, many of the drugs undergo extensive hepatic 
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metabolism (79). The factors governing absorption have a significant impact on 
bioavailability and pharmacokinetics, with huge inter-individual variability being 
a hallmark for most antiretroviral drugs.  
 
The major aim of HIV therapy is to maintain sufficient concentrations of 
antiretrovirals to enable sustained virological suppression. Sub-therapeutic 
concentrations of antiretroviral drugs can allow continued viral replication and 
facilitate development of resistance (80). Particular classes of antiretroviral drug 
are more susceptible to emergence of resistance than others (81). As discussed 
above, NNRTIs have a low genetic barrier to resistance, and class-wide 
resistance can compromises multiple agents in one event (82). 
 
Poor penetration into certain anatomical sites enables continued viral replication, 
and is a major limitation to antiretroviral therapy. Areas such as the CNS, genital 
tract and the lymphatic system have been shown to have low concentrations 
(termed sanctuary sites), which may be involved in viral rebound and resistance 
(83). Recently, it has been demonstrated that despite viral suppression in the 
blood (the current marker of successful treatment) there is incomplete 
suppression and in some cases higher viral replication in lymphoid tissue of 
patients receiving key antiretroviral drugs (84).  
 
There are currently limited paediatric formulations of antiretrovirals. Significant 
differences are apparent in children due to the changes during development.  For 
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example, neonates (children below 6 months) show increased clearance of 
lopinavir and children below 6 years old show increased renal excretion of 
lamivudine (85). Gastric pH is higher during the first 2 years of life, and plasma 
protein, water content and expression of CYPs vary significantly from adults 
(85). Therefore, difficulties in treating children in resource-limited settings are 
exacerbated by the limited availability of paediatric formulations, cost and issues 
with stability and storage. 
 
The efficacy of combination antiretroviral therapy for HIV patients who take 
their medications appropriately is approximately 90% with the main factors that 
distinguish one regimen from another being simplicity (dose, format, size) and 
toxicity (86). A number of toxicities have been reported clinically across the 
various classes of antiretrovirals and have been extensively reviewed (86-88). 
Currently, efavirenz and nevirapine are the two most frequently prescribed 
NNRTIs. This is because both drugs are highly potent (efavirenz inhibition 
constant of the reverse transcriptase enzyme [Ki] = 2.9 nM, nevirapine Ki = 7.0 
nM) and generally well tolerated (89, 90). However, both drugs are associated 
with distinct toxicity profiles. Efavirenz is associated with a series of 
neuropsychiatric adverse effects such as anxiety, depression, hallucinations, 
paranoia and suicide ideation, as discussed in section 1.4.1 (91).  
 
Some nanotechnologies are being applied to extend the pharmacokinetic 
exposure of drug for long-acting (LA) delivery (see below). Clearly, the presence 
of hypersensitivity reactions (HSRs) means care must be taken in selection of 
  26 
drugs for this approach. Moreover, since the low frequency of HSRs mean they 
are not usually detected until late in development (or routine use) the application 
of these types of approach to new chemical entities (NCE) requires careful 
consideration. 
 
1.5.1 Utilisation of Nanomedicine to Address The Limitations of 
Current Antiretroviral Therapeutics  
Collectively, the major drivers for the application of nanotechnology to improve 
the pharmacology of antiretroviral drugs relate to improved pharmacokinetics 
(lower dose / sustained release / lower inter-patient variability), targeting of 
sanctuary sites and improved safety. Clearly, the disease-specific development of 
nanomedicines needs to consider the pathology of the disease, particularly where 
perturbation of the immune system occurs as a function of the disease. However, 
chronicity is important in the context of nanomedicine development since in the 
absence of eradication, patients require a life-long commitment to therapy. 
Nanotechnology can be applied to NCEs or existing therapeutic agents and for 
the latter, the specific toxicological mechanisms for the drugs being employed 
needs to be considered. Despite the significant advances in antiretroviral therapy, 
it is clear that many aspects of modern antiretroviral therapy may be improved. 
The development of NCE can be prohibitively expensive and drugs are often 
abandoned due to inherent issues in drug exposure, efficacy and/or toxicity. 
Nanotechnology offers the opportunity to examine existing pharmaceutical 
agents and address inherent issues in pharmacokinetics (poor absorption, rapid 
clearance, unfavourable tissue distribution, etc.) whilst maintaining the 
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favourable properties of the drug (92). Nanoformulation has been applied to 
address many of the challenges associated with current antiretroviral therapy, 
including LA formulations, improving dissolution of poorly water soluble drugs, 
reduction of inter-individual pharmacokinetic variability, paediatric formulations 
and targeting to HIV-infected cells. This section will outline how nanomedicine 
has been applied to address some of the challenges associated with existing HIV 
therapeutics. 
 
1.5.3 Nanotechnology-enabled oral drug delivery 
As discussed above, one of the limitations of current antiretroviral therapy is 
poor bioavailability following oral administration (77), often as a result of low 
aqueous solubility. Figure 5 shows currently recommended antiretrovirals by the 
WHO and their aqueous solubility. The Biopharmaceutics Classification System 
(BCS) categorises drugs on solubility and permeability (class 1 high solubility 
with high permeability, class 2 low solubility with high permeability, class 3 high 
solubility with low permeability and class 4 low solubility with low 
permeability) (93). Many of the first line HIV drugs have inherent solubility or 
permeability issues. Efavirenz is the preferred antiretroviral agent prescribed. 
When efavirenz is not tolerated nevirapine is frequently prescribed instead. Both 
drugs are classified as having solubility issues. Additionally, lopinavir and 
ritonavir (a frequently prescribed second line therapy) are also classified as 
having solubility issues (BCS class 2) (93). There are many approaches under 
investigation for the development of nanomedicines for oral administration and 
current progress is summarised below. 
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Figure 5. Antiretrovirals recommended by the WHO and their BCS classification. The following 
combinations are recommended for first line therapy; zidovudine and lamivudine supported by 
either efavirenz or nevirapine or tenofovir and emtricitabine supported by either efavirenz. Also 
shown are the biopharmaceutics classification System (BCS) classifications and log P values 
(oil/water distribution). Classification is based on the antiretrovirals physiochemical properties 
and permeability through biological membranes, such as the gut. Data extracted from (77, 94).  
 
Lopinavir is a substrate for both CYP3A4 and P-gp, which both contribute to 
poor bioavailability of lopinavir when administered alone. Conventional therapy 
minimises this by boosting the pharmacokinetics (pharmacoenhancement) of 
lopinavir via co-administration of ritonavir, which potently inhibits both 
CYP3A4 and P-gp (95, 96). Surfactant-stabilised lopinavir SDN ([solid drug 
nanoparticle] also known as nanosuspension or nanodispersion) prepared by 
combination of antisolvent precipitation and high-pressure homogenisation 
(stabilized by polyvinyl alcohol) followed by a stepwise freeze-drying cycle 
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(using mannitol as the cryoprotectant) have been studied. Oral administration of 
lopinavir nanoparticles (12 mg/kg) demonstrated increased plasma exposure 
when compared to conventional lopinavir (12 mg/kg) co-administered with 
ritonavir (3 mg/kg), Cmax (2207 vs 1160 ng/ml), AUC (99806 vs 32002 ng.h/ml) 
and oral bioavailability was increased 3.1 fold. Additionally, co-administration of 
ritonavir with the nanoformulated lopinavir yielded a 3.3-fold greater oral 
bioavailability when compared to the conventional formulation. These data 
indicate that the nanoformulation provides increased oral bioavailability without 
reliance on ritonavir (which is not well tolerated due to toxicity), raising the 
possibility of dose simplification (95). 
 
SDN formulation of efavirenz has also been demonstrated to improve in vitro 
cellular uptake, in vivo plasma pharmacokinetics and reduce in vitro toxicity 
indicating the approach may provide a suitable oral treatment for HIV. SDNs of 
efavirenz were generated using a novel emulsion template freeze-drying 
technique. The process yielded amorphous SDNs of average size 322 nm (±29), 
poly dispersity index 0.48 (±0.17) and drug loading of 70% (70% EFV, 20% 
poly[vinyl alcohol] and 10% α-tocopherol polyethylene glycol succinate) (97). 
Pharmacological assessment of the efavirenz SDN formulation demonstrated 
improved Caco-2 uptake (between 1.1 and 1.65 fold) and apparent permeability 
(up to five-fold), compared to an unformulated efavirenz preparation. Lower 
cytotoxicity was observed (up to 3.5 fold increase in the IC50) compared to an 
unformulated efavirenz preparation. In vitro in vivo extrapolation predicted that 
the SDN formulation could achieve similar plasma pharmacokinetics to the 
standard formulation with 50% less dose (300mg SDN vs 600mg standard 
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efavirenz). The in vivo pharmacokinetics were also investigated via oral 
administration to rats and higher Cmax (478.1 vs 125.9 ng/l), minimum plasma 
concentration ([Cmin]; 378.9 vs 80.5 ng/l), AUC (1831.0 vs 457.1 ng.l/h) and time 
to reach maximum plasma concentration (Tmax; 0.5 vs 0.8h) were observed when 
compared to a conventional formulation. These data indicate a potentially higher 
absorption of efavirenz following oral administration, which in turn may reduce 
dose and cost of efavirenz-containing therapy (97). 
 
1.5.3 Nanotechnology-enabled parenteral drug delivery 
Two LA nanoformulations for the treatment of HIV are currently in late stage 
development and have already transitioned into human studies. LA formulations 
are of particular interest in the treatment of chronic conditions such as HIV 
where patient adherence presents a significant issue (98). Poor adherence to 
therapy can lead to sub-therapeutic concentrations of antiretrovirals, which in 
turn can lead to viral rebound, and the emergence of viral resistance (81). LA 
formulations aim to reduce the impact of poor adherence by increasing the 
dosing interval while maintaining therapeutic concentrations. 
 
The first example is a SDN suspension of the NNRTI, rilpivirine (TMC278). 
Rilpivirine has been approved for oral administration since 2011. Despite 
displaying potent antiviral activity, rilpivirine has poor water solubility 
(<0.1mg/ml) making it compatible with the continuous wet-bead milling process, 
forming SDN suspended in aqueous vehicle with hydrophilic surfactants. 
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Following a single SC or intramuscular injection of rilpivirine, plasma 
concentrations remained detectable for up to 3 weeks in mice and 3 months in 
dogs (99). Following pre-clinical assessment, phase I trials of rilpivirine LA have 
commenced. A single injection of 300 mg/ml rilpivirine LA administered as 
gluteal intramuscular or abdominal SC injections was assessed in 51 healthy 
volunteers. Rilpivirine concentrations remained >10 ng/ml for up to 26 weeks 
with no grade 3 or 4 adverse events (100).  
 
The second example of an LA formulation is that of cabotegravir 
(S/GSK1265744), also produced by wet-bead milling. Cabotegravir is an 
analogue of the integrase inhibitor dolutegravir under assessment for both oral 
and LA administration (101). The LA formulation consists of crystalline 
cabotegravir, milled to a median particle size of 200 nm, along with surfactant, 
polymer, tonicity agent and water for injection. In a randomized, placebo-
controlled phase I study, 56 HIV healthy volunteers received cabotegravir as an 
intramuscular injection (100, 200, 400 or 800 mg) or a SC injection (100, 200 or 
400 mg) or placebo injection. Plasma concentrations of cabotegravir increased 
rapidly over the first week followed by sustained exposure for >24 weeks 
following administration of >200 mg. Intramuscular and SC injection were well 
tolerated with no grade 2 to 4 injection site reactions reported (102). 
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1.6 The Application of Physiologically Based Pharmacokinetic 
Modeling to HIV Therapy 
There has been much advancement in HIV therapy however as previously 
discussed, in section 1.5; there are still many clinical issues with current 
therapeutics. Development of NCE is frequently difficult and expensive. The 
application of physiologically based pharmacokinetic modeling (PBPK) offers 
the opportunity to examine clinical issues in silico, testing the properties of NCE 
or novel formulations aiding in the identification of desired properties (103). 
 
PBPK modelling is a bottom up approach to simulate clinical scenarios using 
virtual patients. The approach mathematically describes physiological processes 
by exploiting the relationship between anthropometric measures (such as height, 
weight and gender) and physiological parameters (such as organ volumes and 
blood flow) (104). For example whole organ weight may be predicted by 
allometric scaling to height, age and body surface area (104). In addition to 
physiological variables, drug specific physicochemical properties (such as logP, 
Caco-2 apparent permeability and affinity for transporters and metabolic 
enzymes) are used as input to predict the pharmacokinetics (105).  
 
PBPK modeling has been applied previously to investigate clinical issues 
applicable to HIV and development of novel nanotherapeutics. As previously 
discussed in section 1.4.1, the CNS toxicities associated with efavirenz have an 
element of dose dependency. Siccardi et al demonstrated that PBPK modeling 
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could be applied to investigate the effect of dose reduction on the 
pharmacokinetics of efavirenz when stratified for CYP2B6 genotype. The 
simulations showed that patients homozygous for CYP2B6 516TT (slow 
metabolisers of efavirenz) were at an increased risk of developing CNS toxicity 
following a standard 600mg once daily oral dose of efavirenz (25% vs. 36% in 
patients with CYP2B6 516GG wild type). Following dose adjustment the 
simulations predicted a lower risk of CNS toxicity without compromising viral 
efficacy. A once daily dose of 200mg achieved 20% probability of CNS toxicity 
with 72% probability of viral suppression (105). 
 
More recently PBPK, has been applied to the development of LA injectable 
nanoformulated antiretrovirals (106). As discussed in section 1.5, administration 
of current antiretrovrals is predominantly via the oral route. The inherent 
disadvantages of oral administration (reduced pharmacokinetics and poor patient 
adherence) may be overcome by the development of LA nano formulated 
antiretrovirals, as discussed in section 1.5.3.  
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1.7 Thesis aims 
Efavirenz has been available for the past 17 years and is still one of the most 
frequently prescribed antiretroviral therapeutics. This can be attributed to its 
beneficial pharmacological properties (antiviral efficacy, long plasma half-life 
[t1/2] and comparatively favourable toxicity profile versus other antiretrovirals) 
(66). Despite these favourable attributes efavirenz has several limitations, which 
may negatively impact therapy, most notably the occurrence of CNS 
disturbances. Although contributing factors have been identified, the underlying 
mechanism of efavirenz associated CNS toxicity remains elusive. In addition to 
CNS toxicity, the poor water solubility of efavirenz potentially reduces 
bioavailability and limits administration to paediatrics. 
 
Various nanotechnologies have been explored in attempts to mitigate some of the 
limitations with efavirenz. While there has been progress in increasing the 
bioavailability of efavirenz there has been no attempt to assess the impact of 
increased exposure to efavirenz on CNS toxicity.  
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The body of work presented in this thesis aimed firstly to investigate the 
underlying mechanism of efavirenz CNS toxicity and secondly to assess uptake 
and CNS toxicity of efavirenz and a novel SDN formulation of efavirenz.  
• Chapter 2 genotyping of patients with early discontinuation of efavirenz 
containing therapy. This chapter investigated the association of single 
nucleotide polymorphisms (SNP’s) in the gamma aminobutyric acid 
receptor (GABA) with early treatment discontinuation of efavirenz was 
investigated.  
• Chapter 3 examined the effect of efavirenz and the SDN formulation in a 
rodent model of anxiogenesis. The EPM has been used previously to 
demonstrate anxiety (a symptom of efavirenz CNS toxicity).  
• Chapter 4 details the development of a liquid chromatography mass 
spectrometry assay for the detection of efavirenz in plasma, brain tissue 
homogenate, PBS and cell culture media.  
• Chapter 5 the uptake of efavirenz and the SDN formulation was 
investigated in hCMEC/D3 cell line, immortalised endothelial cells from 
the BBB. This chapter investigated the effects of inhibitors of transport 
proteins and multiple mechanisms of endocytosis. 
• Chapter 6 discusses the generation of a PBPK model to predict efavirenz 
penetration in plasma, CSF and brain tissue. Currently CSF 
concentrations are used as a surrogate for brain penetration of drugs. This 
chapter investigated if brain concentrations were represented by CSF 
concentrations in an in silico simulation. 
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Chapter 2 
 
Single nucleotide polymorphisms in the GABAa receptor are not 
predictors of early treatment discontinuation of efavirenz  
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2.1 Introduction 
As discussed in chapter 1, efavirenz is one of the key therapeutics currently used 
in the treatment of HIV. Efavirenz, supported by an NRTI backbone, is currently 
recommended as first-line therapy by multiple health organisations (26, 64). 
There is an abundance of reports from clinical trials detailing CNS disturbances 
such as depression, anxiety, abnormal dreams, suicidal thoughts and 
hallucinations. CNS adverse effects have been shown to have a high rate of 
occurrence. Reports of >50% of patients experiencing CNS toxicities are not 
uncommon. CNS disturbances have been reported to occur transiently in the 
majority of patients. Symptoms have been reported to develop shortly after 
taking efavirenz, subsiding within 2 to 4 weeks. Although CNS adverse effects 
dissipate in the majority of patients, there is a minority (up to 10%) of patients 
who continue to experience neuropsychiatric adverse effects while receiving 
efavirenz. The CNS toxicities associated with efavirenz are well documented but 
the underlying mechanisms have remained elusive.  
	
Although there have been numerous studies to identify predictors of efavirenz 
CNS toxicity, until recently the majority of studies have investigated 
polymorphisms in genes determining efavirenz disposition. Given the majority of 
efavirenz toxicities are mood and sleep disorders (Table 1) there is evidence to 
indicate an interaction with neurotransmitters. Treatment of naturally occurring 
depression and anxiety focuses on pharmacological modulation of 
neurotransmission. There are numerous classes of antidepressants that act to via 
distinct mechanisms. Serotonin is released at the synaptic cleft to interact with 
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serotonin receptors. Cessation of signalling is achieved by reuptake of serotonin. 
Selective serotonin reuptake inhibitors (such as fluoxetine) act via inhibiting 
reuptake and increasing the duration of serotonin signaling (107). Monoamine 
oxidase inhibitors (such as moclobemide) also act to increase the duration of not 
only serotonin signaling but also dopamine by inhibiting the metabolism of 
monoamine neurotransmitters (107). Anxiety is frequently treated by the 
administration of benzodiazepines (such as diazepam). Benzodiazepines act via 
allosteric modulation, binding to the benzodiazepine binding site leads to 
potentiation of GABAergic signaling. Additionally, benzodiazepines are 
indicated in the treatment of insomnia (108). There are numerous 
neurotransmitters implicated in the etiology of abnormal dreams or nightmares. 
Clinical trials and case reports have demonstrated drugs effecting acetycholine 
(e.g. donepezil, an acetycholinesterase inhibitor), norepinephrine (e.g atenolol, a 
β1 receptor antagonist), serotonin (e.g paroxetine, a selective serotonin reuptake 
inhibitors) and GABA (e.g nitrazepam, acts via increasing binding affinity of 
GABA to GABA receptors) (109). 
 
The GABA receptor is the principle mediator of inhibitory neurotransmission in 
the CNS (110). The receptor is a hetero pentameric ligand gated ion channel, 
assembled from a combination of 5 subunits leading to the formation of a 
chloride ion channel (111). Currently there have been 16 different subunits 
identified (α1-6, β1-3 γ1-3, δ, ε, π and ϴ), with the most common receptor type 
consisting of 2 α1 subunits, 2 β2 subunits and 1 γ2 subunit (Figure 1) (111, 112). 
The GABAa receptor has been of significant pharmacological interest, as 
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dysfunctions of GABAergic signalling have been implicated in neurological 
disorders including anxiety, insomnia and depression (110, 113, 114). The 
GABAa receptor has a variety of binding sites; one of the most 
pharmacologically interesting is the benzodiazepine-binding site. The 
benzodiazepine binding site is situated at the interface between the α1 and γ2 
subunits (18). Binding of ligands to this allosteric binding site increases the 
affinity of the receptor for GABA, thus potentiating GABAergic signalling (115).  
 
 
Figure 1 shows the configuration of the extracellular domain of the GABAa receptor. Labelled 
are the subunit type (α1, β2, and γ2), the 2 GABA binding sites and the benzodiazepine-binding 
site. 
 
Examination of the adverse effects of drugs acting at the benzodiazepine receptor 
reveals a similar profile of adverse effects as displayed by efavirenz (see Table 
1). Additionally, efavirenz is a 1,4-dihydro-2H-3,1-benzoxazin-2-one, which 
shares a number of structural motifs with the benzodiazepines (116). Previous in 
silico studies (conducted as part of a previous Master by Research degree) 
performed using homology-modelling techniques have identified that efavirenz 
and ligands of the benzodiazepine binding site share a common docking location 
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(Figure 2). The docking results demonstrated that efavirenz and its metabolites 
did not share any common docking locations with ligands of the GABA binding 
site. However, models indicated that efavirenz may dock in a similar location to 
benzodiazepine ligands, showing the potential of efavirenz to interact with key 
amino acids involved in binding of ligands at this site (117). 
 
 
Figure 2 shows the docking results performed using the benzodiazepine-binding site. Each grid 
shows the most energetically favourable docking position of the following molecules: A – 
efavirenz (green), B - efavirenz (green), diazepam (blue) and zolpidem (orange), C –7-OHEFV 
(green), 8-OHEFV (blue), 8,14-OHEFV (orange), D – nevirapine (green), delavirdine (blue), 
rilpivirine (orange). Also shown in each grid are the amino acid residues shown to be important 
in benzodiazepine binding His 101, Tyr 161, Thr 160 (α1 purple) Phe77 and Met 130 (γ2 yellow). 
Data from this figure was generated during a previous Master by Research degree (unpublished 
data). 
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Drug Side Effects 
Efavirenz 
Abnormal dreams, anxiety, depression, insomnia, aggression, 
confusional state, euphoric mood, hallucination, mania, suicide 
ideation, disturbance in attention, dizziness, headache, somnolence, 
agitation, amnesia, ataxia, abnormal coordination, convulsions and 
abnormal thinking. 
Zolpidem 
Hallucination, agitation, nightmare, somnolence, headache, 
dizziness, exacerbated insomnia and anterograde amnesia. 
Zalepon 
Amnesia, paraesthesia, somnolence, ataxia, confusion, decreased 
concentration, apathy, depersonalisation, depression, dizziness and 
hallucinations. 
Flurazepam 
Numbed emotions, reduced alertness, confusion, fatigue, headache, 
dizziness, muscle weakness, ataxia, and double vision. 
Lorazepam Confusion, depression, Sedation, drowsiness, ataxia and dizziness. 
Diazepam 
Sedation, drowsiness, unsteadiness, ataxia, headache, vertigo and 
visual disturbances. 
 
Table 1 shows the chemical structure and side effects associated with efavirenz and 
drugs acting on the GABA receptor (in particular acting on α1 GABAa receptor). 
 
When considering the associated side effects and structural similarities to 
GABAergic drugs, it is reasonable to postulate that the mechanism of efavirenz 
mediated CNS side effects is via modulation of GABAergic signalling. The aim 
of this chapter was to investigate the association of single nucleotide 
polymorphisms (SNP’s) in the subunits of the GABA receptor (α1+2, β2 and γ2) 
with early treatment discontinuation of efavirenz containing therapy (Table 2). 
This genetic association study was performed using patient samples of the 
German Competence Network for HIV/AIDS (KompNet Cohort). Allele 
frequencies were compared between patients recorded as early treatment 
discontinuation (efavirenz treatment for < 3 months) and patients maintaining 
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efavirenz-containing therapy (≥ 3 months).  In this study early treatment 
discontinuation was employed as a surrogate marker for CNS disturbances. 
 
SNP code GABA 
Subunit 
Alleles Population Frequency Disease 
Association 
References 
Rs279858 α2 A/G (A) E = A (0.527), G (0.473) 
SSA = A (0.823), G (0.177) 
Alcoholism  (118) 
Rs279845 α2 A/T (T) E = A (0.492), T (0.508) 
SSA = A (0.149), T (0.851) 
Alcoholism (119) 
Rs279836 α2 A/T (T) E = A (0.492), T (0.508) 
SSA = A (0.149), T (0.851) 
Alcoholism (120) 
Rs2229944 β2 C/T (T) E = C (0.951), T (0.049) 
SSA = C (0.810), T (0.190) 
Schizophrenia (121) 
Rs6556547 β2 A/C (C) E = A (0.059), C (0.941) 
SSA = A (0.126), C (0.874) 
Schizophrenia (121) 
Rs211037 γ2 C/T (T) E = C (0.768), T (0.232) 
SSA = C (0.455), T (0.545) 
Epilepsy (122) 
Rs211014 γ2 A/C (C) E = A (0.195), C (0.805) 
SSA = A (0.467), C (0.533) 
Heroin 
Addiction 
(123) 
 
Table 2 shows the SNPs examined in the GABAa receptor. Also 
shown are the subunit affected by the SNP, alleles (bracket indicates 
common allele) and disease association. Population frequencies were 
gathered from International Hapmap Project. E = European and SSA 
= Sub-Saharan African. 
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2.2 Methods 
 
2.2.1 Materials 
QIAamp DNA mini kit genomic DNA isolation kit was purchased from Qiagen 
(Manchester, UK). Pre validated primers and probes were purchased from Life 
Technologies (Paisley, UK). Quantitative polymerase chain reaction (QPCR) 
master mix was purchased from ABgene (Loughborough, UK). All other 
consumables were purchased from Sigma Aldrich (Dorset, UK). 
 
2.2.2 Patient Information 
Blood samples were taken from 439 patients receiving an efavirenz-containing 
regimen. The 439 patient samples were then assigned to either a training cohort 
(samples analysed by LGC Genomics [formerly KBioscience], 288 patients) or 
test cohort (samples analysed in house, 151 patients). Each cohort was 
subdivided based on duration of efavirenz therapy, the control group and the 
early discontinuation group. In addition to blood samples the details on the 
following demographic factors were collected from each patient; gender, 
ethnicity, age, smoking status and duration of efavirenz therapy. Blood samples 
were collected from patients of the cohort of the German Competence Network 
for HIV/AIDS (KompNet). The ethics committee of the Ruhr-Universita ̈t 
Bochum (Germany) granted ethical approval and patient consent was sought 
prior to collection of patient samples. 
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2.2.3 Extraction of Genomic DNA  
Genomic DNA was extracted from whole blood using the QIAamp mini kit. 
Extraction was performed following manufacturer’s instructions (spin-column 
protocol). Patient samples (200µl) were mixed with 20µl of QIAGEN protease 
and 200µl of buffer AL in microcentrifuge tubes. Samples were thoroughly 
mixed to ensure sample lysis followed by incubation at 56°C for 10 minutes. 
Following incubation, 200µl of ethanol was added to each sample and transferred 
to fresh spin-columns and centrifuged at 6000g for 1 minute at room 
temperature. 500µl of buffer AW1 was added and samples were then centrifuged 
at 6000g for 1 minute at room temperature. 500µl of buffer AW2 was added and 
samples were the centrifuged at 20,000g for 3 minutes at room temperature. 50µl 
of distilled water was added to each sample and incubated at room temperature. 
DNA was eluted by centrifugation at 6000g for 1 minute at room temperature. 
DNA was quantified using PicoGreen dsDNA quantitation reagent and 
normalised to 20ng/µl. The samples were stored at -40°C until analysis by real-
time polymerase chain reaction (PCR) allelic discrimination or until shipping to 
LGC Genomics for analysis.  
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2.2.4 Genotyping of GABA Receptor Polymorphisms by qPCR-
based allelic discrimination  
Genotyping for Rs279858, Rs279845, Rs279836, Rs2229944, Rs6556547, 
Rs211037 and Rs211014 in the test cohort was conducted LGC genomics. 
Genotyping was conducted using LGC Genomics proprietary KASP genotyping 
technology. Primers and Probes were designed using LGC Genomics proprietary 
software, Kraken™ (124). 
 
The PCR reaction mixture consisted of 10µl master mix, 1µl primer and probe, 
1µl of genomic DNA and 8µl of ultra-pure DNase free water for a total reaction 
volume of 20µl. Primers and probe assays were purchased from Life 
Technologies Rs211014 (pre-validated assay, ID C_3169569_1_) and 
Rs6556547 (custom assay, primer and probe sequences are below). Thermal 
cycling was conducted using a DNA Engine Opticon 2 system (MJ Research 
Inc., USA) programmed for standard cycling conditions (95˚C for 15 min, 
followed by 40 cycles of 95˚C for 15 s and 60˚C for 1 min). 
 
Rs6556547 forward sequence  5′TCTGAAACTAGTAATAAATTGCTCACATAAAGACA3′ 
Rs6556547 reverse sequence 5′GCAAATATCCCATTTTTCCAAAGTTGAAAC3′ 
Rs6556547 probe sequence 5′TTGTTCCTGTAATCGATAC3′ 
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2.2.5 Statistical analysis  
All data are expressed as median (± interquartile range [IQR]). Univariate and 
multivariate analyses were performed by the χ2 test and backward logistic 
regression respectively. Statistical significance was established as P < 0.05 with a 
statistical trend established as < 0.1. All statistical tests were performed using 
SPSS statistics (v22). All genotypes were assessed for Hardy-Weinberg 
equilibrium by the χ2 test using the Hardy-Weinberg equilibrium online 
calculator (125). 
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2.3 Results 
 
2.3.1 Cohort Demographics 
Patients for this study were recruited between the 1st of January 2006 and the 1st 
of October 2009. The baseline patient demographics for the training cohort and 
the test cohort are shown in Table 3 and Table 4 respectively. There were 237 
and 100 patients receiving efavirenz containing therapy for over 3 months, 
constituting the control groups, in the training cohort and the test cohort 
respectively. There were 51 and 48 patients recorded as discontinuing efavirenz-
containing therapy early (less than 3 months) in the training cohort and the test 
cohort, respectively. 
 
 Sustained therapy  
(> 3 months) 
Early Treatment 
Discontinuation (< 3 
months) 
Total 
Number of Patients 237 (82.3%) 51 (17.7%) 288 (100%) 
Gender (male) 152 (64.1%) 38 (74.5%) 190 (66%) 
Ethnicity (White) 155 (65.4%) 42 (82.4%) 197 (68%) 
Age 45 (40-53) 43 (39-51)  
Smoking Status (non 
smoker) 
56 (23.6%) 19 (37.3) 75 (26%) 
 
Table 3 shows the demographics collected for the training cohort including gender, 
ethnicity, age, smoking status and duration of efairenz containing therapy. Data 
represents frequency with percentage shown in brackets (gender, ethnicity, smoking 
status) or median with interquartile range shown in brackets (age). 
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 Sustained therapy  
(> 3 months) 
Early Treatment 
Discontinuation 
(< 3 months) 
Total 
Number of Patients 100 (67.6%) 48 (32.4%) 151 (100%) 
Gender (male) 81 (81%) 45 (93.8%) 126 (83%) 
Ethnicity (White) 72 (72%) 46 (95.8%) 118 (78%) 
Age 46 (41-53) 45.5 (42-50.8)  
Smoking Status 
(non-smoker)  
20 (20%) 12 (25%) 32 (21%) 
 
Table 4 shows the demographics collected for the test cohort including gender, ethnicity, age, 
smoking status and duration of efairenz containing therapy. Data represents frequency with 
percentage shown in brackets (gender, ethnicity, smoking status) or median with interquartile 
range shown in brackets (age). 
 
2.3.2 Association of Demographic Factors with Early Treatment 
Discontinuation, Univariate Analysis 
Patient demographics (gender, ethnicity, smoking status and age) were tested for 
a univariate association with early treatment discontinuation of efavirenz 
containing therapy. The training cohort (Figure 3) revealed no association with 
early treatment discontinuation and age or gender, P = 0.78 and 0.17, 
respectively. Both ethnicity and smoking status were associated with early 
treatment discontinuation. Patients of white ethnicity showed a greater degree of 
early discontinuation (21.3% of patients with white ethnicity discontinued 
efavirenz vs 10.0% of patients with black ethnicity P = 0.02). There was a higher 
degree of discontinuation in non-smokers vs smokers (25.3% of patients that 
were non-smokers discontinued efavirenz vs 21.1% of patients that smoked, P = 
0.02). 
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Figure 3 shows the univariate analysis of the training cohort for gender, ethnicity, smoking status 
and age. Also shown are the P values generated via the χ2 test. 
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Figure 4 shows the univariate analysis of the test cohort for gender, ethnicity, smoking status and 
age. Also shown are the P values generated via the χ2 test. 
 
The test cohort revealed no association with early treatment discontinuation and 
age or smoking status, P = 0.61 and 0.59, respectively (Figure 4). Both ethnicity 
and gender were associated with early treatment discontinuation. Patients of 
white ethnicity showed a greater degree of early discontinuation (39.0% of 
patients with white ethnicity discontinued efavirenz vs 6.7% of patients with 
black ethnicity P = 0.02). There was a higher degree of discontinuation in males 
(35.7% of male patients discontinued efavirenz vs 13.6% of female patients P = 
0.02). 
  52 
2.3.3 Association of GABA SNPs With Early Treatment 
Discontinuation, Univariate Analysis  
Hardy-Weinberg equilibrium was assessed for all genotypes in both the training 
and test cohorts. Rs211037 was found not to be in Hardy-Weinberg equilibrium 
(P > 0.01), all other genotypes were in Hardy-Weinberg equilibrium (P < 0.05). 
 
Patient blood samples were genotyped for SNPs in GABA subunits and tested for 
a univariate association with early treatment discontinuation of efavirenz 
containing therapy. The training cohort (Figures 5) revealed no association with 
early treatment discontinuation.  
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Figure 5 shows the univariate analysis of the training cohort for SNPs in the GABA receptor 
subunits (Rs279858, Rs211014, Rs2229944, Rs6556547, Rs211037, Rs279845 and Rs279836). 
Black bars indicate homozygous common allele, light grey indicate heterozygous and dark grey 
indicate homozygous variant alleles. Also shown are the P values generated via the χ2 test. 
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The data was further examined by performing carrier/non-carrier analysis (Table 
5). Although no significant associations were determined, 2 SNPs were found to 
be trending towards significance when analysed for carrier/non-carrier 
relationship. There was a lower degree of discontinuation in patients with the 
homozygous variant allele in Rs211014 (2% of patients homozygous for the 
variant allele vs 8.4% of patients homozygous common allele and heterozygous 
variant allele, P = 0.1). The converse was observed with Rs6556547. A higher 
rate of discontinuation was observed in patients with the homozygous 
polymorphism (3.9% of patients homozygous for the variant allele vs 0.8% of 
patients homozygous Common allele and heterozygous variant allele, P = 0.09). 
As a trend towards significance was identified with Rs211014 and Rs6556547, 
these two SNPs were further investigated in the test cohort. 
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Figure 6 shows the univariate analysis of the test cohort for SNPs in the GABA receptor subunits 
(Rs211014 and Rs6556547). Black bars indicate homozygous common allele, light grey indicate 
heterozygous and dark grey indicate homozygous variant alleles. Also shown are the P values 
generated via the χ2 test. 
 
Analysis of Rs211014 and Rs6556547 in the test cohort did not show an 
association with early treatment discontinuation, P = 0.74 and 0.54, respectively 
(Figure 6). As with the training cohort, the genotypes a carrier/non-carrier 
analysis was performed. Rs211014 showed no significant difference in the rate 
of discontinuation when the heterozygotes were grouped with the common allele 
(40.0% of patients homozygous for the variant allele vs 32.2% of patients 
homozygous common allele and heterozygous variant allele, P = 0.71) or the 
variant allele (36.6% of patients homozygous for the variant allele and 
heterozygous variant allele vs 30.0% of patients homozygous common allele, P = 
0.59. There were no homozygous variant alleles for Rs6556547 in the test cohort, 
precluding further univariate analysis. 
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2.3.4 Association of GABA SNPs With Early Treatment 
Discontinuation, Multivariate Analysis 
As ethnicity and smoking status were revealed to have a significant association 
and both Rs211014 and Rs6556547 (when common allele and heterozygotes 
were compared against homozygous variant alleles) were found to trend towards 
significance, these 4 variables were considered in the multivariate analysis of the 
training cohort. The multivariate analysis (Table 6) showed neither Rs211014 
and Rs6556547 were associated with early treatment discontinuation. Both 
Ethnicity and smoking status showed a strong association, P = 0.001 and P < 
0.001 respectively.  
 
Covariate Odds Ratio P value 
Ethnicity 0.25 (0.11-0.54) 0.001 
Smoking Status 0.37 (0.23-0.59) <0.001 
Rs211014 NS 0.28 
Rs6556547 NS 0.11 
 
Table 6 shows the results of the multivariate analysis of the training cohort for ethnicity, 
smoking status, Rs211014 and Rs6556547 (when widtype and heterozygotes were compared 
against homozygous variant alleles). Also shown are the odds ratio (confidence interval) and P 
value. NS = not significant. 
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In the test cohort Rs211014 and Rs6556547 were not shown to be significant in 
the univariate analysis. Only ethnicity and gender were shown to be significant 
and included in the multivariate analysis (Table 7). Only ethnicity was 
determined to be significantly associated with early treatment discontinuation. 
 
Covariate Odds Ratio P value 
Ethnicity 0.13 (0.29-0.62) 0.01 
Gender NS 0.38 
 
Table 7 shows the results of the multivariate analysis of the training cohort for ethnicity and 
gender. Also shown are the odds ratio (confidence interval) and P value. NS = not significant. 
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2.4 Discussion 
There have been multiple previous studies examining genetic associations with 
efavirenz-associated CNS toxicity. Polymorphisms in genes such as CYP2B6, 
constitutive androstane receptor (CAR), ABCG2 (BCRP) and ABCC1 (MRP1) 
have shown an association with of efavirenz associated CNS toxicity (65, 72, 
126). Many of these associations are linked to efavirenz plasma concentrations. 
However, factors influencing plasma concentrations do not fully explain the 
development of CNS toxicity. This is demonstrated by examining ethnicity. 
Despite black patients being at risk of having higher plasma concentrations of 
efavirenz, studies have demonstrated (including the data presented here) that 
black patients show decreased rates of CNS toxicity and treatment 
discontinuation (75). This indicates that confounding factors may be involved in 
the aetiology of efavirenz CNS toxicity. 
 
This study aimed to investigate the association of SNPs in the GABA receptor 
and early discontinuation. Despite an initial trend with Rs211014 and Rs6556547 
in the univariate analysis of the training cohort, these SNPs were not found to be 
significant in the multivariate analysis or in either analysis of the test cohort. 
Although the polymorphisms in the GABAa receptor investigated here did not 
show an association with efavirenz early discontinuation, there is functional 
evidence to support the role of the GABA receptor in efavirenz associated CNS 
toxicity. Gatch et al demonstrated that efavirenz was unable to activate the 
GABA receptor alone. However, efavirenz potentiated signalling in the presence 
of GABA, indicating a mechanism of action analogous to benzodiazepines (127).  
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The selected SNPs examined in this study are in the genes coding for the α2, β2 
and γ2 subunits. Although the α1+2, β2 and γ2 subunits form the most common 
GABA receptor, there are 15 different subunits that can organise in different 
ways to form multiple GABA receptors (111). Figure 7 shows the receptors 
formed from the subunits found in rat brain. Given the wide array of possible 
receptors it is indeed possible that efavirenz may interact with one or more 
GABA receptor subtypes. Therefore, future studies may identify genetic 
associations that implicate GABA receptor subtypes in the development of 
efavirenz-associated CNS side effects. 
 
Figure 7 shows the frequency of GABA receptors and the subunits they are 
composed of. Source (111) 
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Another reason the SNPs examined here showed no association with early 
treatment discontinuation is perhaps the GABA receptor does not play a role in 
CNS toxicity. As previously discussed there are other neurotransmitters 
implicated in the natural occurrence of symptoms associated with efavirenz CNS 
toxicity. Indeed, there is data generated from in vitro and genetic association 
studies supporting the role of neurotransmitters. Recent studies have provided 
evidence to implicate the serotonin receptor 5 hydroxy tryptamine 2A (5-HT2A). 
Efavirenz has been shown to act as a weak partial agonist in cell based assays 
and induces behavior consistent with activation of the 5-HT2A receptor in rodent 
behavioral models (127). The in vitro evidence is supported by data generated in 
humans. Following 7 days of exposure to efavirenz, it was found patients 
suffered several sleep disturbances including reduced time to sleep onset, an 
increase in non-rapid eye movement sleep and reduced performance on an 
attention switching task. Treatment with a 5-HT2A antagonist induced some of 
the effects observed in efavirenz treatment, indicating an interaction with 
efavirenz and the 5-HT2A receptor (128). Additionally it has been shown that the 
SNP 5-HT2A 102C>T has a relationship with reports of sadness in patients 
receiving efavirenz (P=≤0.01, although this was not reported as significant due to 
Bonferroni correction) (65). These data suggest further study into the interactions 
of efavirenz and the serotonin receptors may be warranted. It is worth 
considering that efavirenz CNS toxicities may not be based on interactions with a 
single receptor. The wide array of symptoms of CNS toxicity indicates multiple 
receptors and receptor subtypes may be involved. This may make identifying 
SNPs difficult as susceptibility to efavirenz CNS toxicity may be due to a 
combined effect of polymorphisms in multiple genes coding for CNS receptors. 
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A limitation of this study is treatment discontinuation was used to indicate 
efavirenz CNS toxicity in place of a detailed patient history of CNS disturbances. 
In addition to CNS toxicity, patients may discontinue for virological failure, poor 
adherence. Early treatment discontinuation is assumed to be in response to the 
development of CNS toxicity. However, this surrogate marker for CNS 
disturbance may be insufficient to gauge the true frequency of CNS toxicity 
within the population.  
 
The natural occurrence of conditions such as depression involves a complex 
interplay of factors influencing neurotransmission. This makes identifying single 
predictors of efavirenz CNS toxicity more difficult. The GABA receptor may be 
involved in the aetiology of efavirenz-associated CNS side effect and future 
studies are required to elucidate this potential interaction. 
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Chapter 3 
 
The in vivo effects of solid drug nanoparticle and conventional 
efavirenz on anxiogenesis in rodents 
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3.1 Introduction 
Over the past 30 years there have been remarkable advancements in the therapy 
of HIV. The approach to treatment has evolved from simple monotherapy to a 
complex dosing regimen comprised of multiple drugs from numerous classes 
(129). Despite the significant advances in using this treatment approach, there are 
many aspects of modern antiretroviral therapy that may be improved. For 
example, the development of new pharmaceutical agents can be prohibitively 
expensive and are often abandoned due to inherent issues in drug exposure, 
efficacy and/or safety. Nano-formulation technologies offer the opportunity to 
examine existing pharmaceutical agents and address inherent issues in drug 
pharmacokinetics (poor absorption, rapid clearance, unfavourable tissue 
distribution, etc) whilst maintaining the favourable properties of the drug (92). 
 
The NNRTI efavirenz has been used in first-line therapy of HIV for over 15 
years (130). Efavirenz displays potent activity against wild type HIV-1, IC50 
(against viral replication) 0.51 ng/mL, Ki (inhibition of the RT enzyme) 2.93 
nmol/L and a long t1/2 of 40-76 hours, enabling once daily dosing (57, 89).  
Despite these favourable properties, there are known issues with the 
pharmacokinetics of efavirenz that have the potential to influence therapy. 
Specifically, efavirenz has very poor water solubility (<10µg/ml) that may 
impact negatively on bioavailability by impeding intestinal dissolution and oral 
drug absorption (97). Additionally, pharmacokinetic exposure to efavirenz shows 
a high degree of inter-individual variability in patients (97). Our group have 
previously reported an efavirenz SDN formulation, which attempted to alleviate 
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the issue of poor drug solubility. Utilising an emulsion-templated freeze-drying 
process, SDNs were produced that achieved 70% drug loading. In vitro studies 
showed increased cellular accumulation and reduced cytotoxicity of efavirenz in 
Caco-2 cells while in vivo pharmacokinetic studies performed in rats 
demonstrated an increase in plasma efavirenz concentrations of approximately 4-
fold following a single oral dose (97). 
 
Efavirenz is associated with neurocognitive adverse events, which can negatively 
impact patient treatment (89). Efavirenz CNS toxicity and the negative impact on 
patient adherence are discussed in section 1.4.1. Although the clinical efficacy of 
efavirenz is well characterised, there is a paucity of information regarding the 
underlying mechanisms of efavirenz-associated CNS toxicity, making testing of 
novel efavirenz formulations problematic.  
 
Behavioural pharmacology has been used previously to assess the CNS toxicity 
of efavirenz in both rats and mice (131, 132). Romāo et al demonstrated 
efavirenz significantly altered rodent behaviour in multiple behavioural and 
cognitive performance tests including the elevated plus maze (EPM) (131). 
Efavirenz significantly reduced exploration in the open arm of the EPM, 
indicating an anxiogenic effect of efavirenz. The findings of this study 
demonstrated that efavirenz produced anxiety-like behaviour whereas another 
NNRTI, nevirapine, did not. This supports clinical data, as it has been observed 
in humans that CNS side effects are associated with efavirenz treatment 
discontinuation and not with nevirapine-containing therapy (133). 
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Here we investigated neurocognitive disturbances in rats using the EPM after 
administration of a conventional pre-clinical formulation of efavirenz or SDN 
formulation of efavirenz. In this model, the degree of anxiety was demonstrated 
by the relative proportions of time spent in the open arms versus the closed arms 
and central platform, with greater anxiety linked to less time on the open arms 
(134). In addition to the traditional measures, there are a number of ethological 
measures that may increase the sensitivity of the EPM test. These measures can 
be characterised into two groups, risk-assessing behaviour and behaviour-
indicating sedation. Risk-assessing behaviour includes head dips, stretch attend 
posture, rears and closed arm returns. Sedation is described by periods of 
grooming and other non-exploratory behaviour (135). Recording behaviour 
associated with risk assessment and sedation allows analysis of behaviour whilst 
on the EPM that would otherwise be unaccounted. 
 
Since the mechanisms of efavirenz-associated CNS toxicity are currently 
unknown, there are no in vitro tests that can be applied to assess the impact of 
nanoformulation on the development of efavirenz-associated CNS toxicity. This 
presents a problem with regards to assessing the safety and impact of novel 
formulations of efavirenz. Behavioural pharmacology allows for the pre-clinical 
screening of novel formulations of efavirenz. In this study, the anxiety-like 
behaviour in rats was assessed using the EPM after administration of a 
conventional pre-clinical formulation of efavirenz efavirenz, SDN efavirenz 
formulation or vehicle control. Previously published studies with the SDN 
formulation have demonstrated the potential to increase the exposure of 
efavirenz. As efavirenz exposure has been associated with an increased in 
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occurrence of CNS toxicity (as discussed in section 1.4.1) it was considered 
prudent to assess the incidence of anxiety (one of the symptoms of efavirenz 
associated CNS toxicity) in response to conventional pre-clinical formulation of 
efavirenz and the SDN formulation of efavirenz. 
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3.2 Methods and Materials 
 
3.2.1 Materials 
Male Wistar rats were purchased from Charles River (Oxford, UK) 
Methylcellulose was purchased from Sigma Aldrich (Dorset, UK). Efavirenz 
powder (>98% pure) was purchased from LGM Pharma inc (Boca Raton, USA). 
All other consumables were purchased from Sigma Aldrich (Dorset, UK). 
 
3.2.2 Animals and treatment 
Male Wistar rats (Charles River, UK) weighing 180 – 220g on arrival were used 
in EPM experiments. Animals were singly-housed in the absence of 
environmental enrichment on a normal light cycle. All experimental testing was 
conducted during the light phase of the cycle. Food and water were provided ad 
libitum. All experiments were conducted under appropriate personal and project 
licenses (granted by the Home Office, UK). 
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3.2.3 Emulsion-Templated Freeze-Drying to Form Efavirenz 
Nanoparticles  
Efavirenz SDNs were prepared as described previously (97). In Brief, a mixture 
of efavirenz (dissolved in chloroform) and stabilisers (poly[vinyl alcohol] and α-
tocopherol polyethylene glycol succinate, dissolved in H2O) was prepared in the 
ratio of 70% efavirenz, 20% poly(vinyl alcohol) and 10% α-tocopherol 
polyethylene glycol succinate. The mixture was emulsified using a Covaris S2x 
acoustic homogenisation system (Covaris, MA, USA). Samples were 
immediately freeze-dried leading to the formation of an emulsion template 
porous monolith. SDNs were dispersed in dH2O for use in in vivo experiments. 
 
3.2.4 Drug Treatment 
Wistar rats were assigned to 3 groups (10 rats per group) and dosed with either 
conventional efavirenz (10 mg/kg, 2ml/kg 0.5% methylcellulose in dH2O), SDN 
formulated efavirenz (10mg/kg, 2ml/kg in dH2O) or vehicle control (2ml/kg 
0.5% methylcellulose in dH2O). Dosage was based on individual weight taken 
prior to dosing. Dosing was administered once daily via oral gavage over 5 
weeks.  
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3.2.5 Equipment 
The EPM was a wooden plus shaped maze with a black Plexiglas floor. The 
maze consisted of 2 open arms (10x50 cm), 2 closed arms enclosed with clear 
Plexiglas (10x50x50 cm) and a central platform (10x10 cm). The maze was fixed 
to a black metal base (50cm) to elevate the maze above ground level. The edges 
of the maze were raised (0.5cm) to facilitate retention of the rats. 
 
 
Figure 1 depicts the EPM 
 
3.2.5 Elevated Plus Maze Procedure 
Following weighing and oral dosing the rats were taken back to their home cage 
for 2 hours. The rats were transported individually from the housing room to the 
testing room. Rats were placed on the central square facing an open arm. The test 
was administered for 5 minutes. During testing, the experimenter remained in the 
testing room seated silently in the same position for all tests. At the conclusion of 
the test the rat was returned to its home cage and the maze was thoroughly 
cleaned using ethanol (70% ethanol) wipes and allowed to dry. Testing 
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commenced 7 days after daily dosing was initiated. The EPM was repeated once 
every 7 days for 5 weeks. All tests were recorded for later analysis using a digital 
camera (Samsung DV300F) at an angle of approximately 45°. Digital recordings 
of the EPM were analysed using the Ethowatcher software package 
(http://ethowatcher.ufsc.br). Data was analysed for spatial distribution and 
ethological behaviour (Table 1). 
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Behavioral Measure Description 
Open arm entrance An entrance to open arm is counted as 
4 paws placed on the open arm 
Closed arm entrances An entrance to open arm is counted as 
4 paws placed on the closed arm 
Time in open arm The time (expresses as a percentage of 
total time on the maze) spent on the 
open arm 
Time in closed arm The time (expresses as a percentage of 
total time on the maze) spent on the 
closed arm 
Time on central platform The time (expresses as a percentage of 
total time on the maze) spent on the 
central platform 
Central platform latency Time taken to initially move from 
central square 
Risk assessment The number of occurrences of 
behaviour indicating assessment of the 
environment for potential risk factors 
(stretch attend postures, head dips and 
rearing) 
Sedation The total time spent stationary 
(grooming and non-exploratory 
behaviour) 
 
Table 1 summary of the spatial and ethological measures recorded during exposure to the EPM 
 
3.2.6 Statistics 
All data were assessed for normality using the Shapiro Wilk test. Statistical 
analysis was performed by Mann-Whitney U test and significance was defined as 
P <0.05. All data are given as median with interquartile range [IQR]. 
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3.3 Results 
 
3.3.1 Spatial distribution 
Data for the spatial distribution during the EPM test was collected for the number 
of open and closed arm entrances, the duration of time (expressed as % of total 
time on the maze) in the open arms, closed arms and central platform and the 
central platform latency. The median for each group was plotted against duration 
of treatment (Figure 2). The AUC was calculated for individual rats in order to 
examine the effect of each condition over the period of dosing. The median AUC 
of each group was plotted (Figure 3) and compared for statistically significant 
differences. 
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Figure 2 show the behavioral measures plotted against time from the EPM for control (Con), 
conventional efavirenz (EFV) and solid drug nanoparticle efavirenz (SDN). The graphs display 
time plotted against spatial measurements open arm entrances (A), closed arm entrances (B), time 
in open arm (C), time in closed arm (D), time on central platform (E) and central platform latency 
(F). Data points represent median with interquartile range. N = 10. 
 
  76 
 
 
Figure 3 shows the AUC (for each of the measurements displayed in Figure 2) for vehicle 
control, conventional pre-clincial formulation of efavirenz (EFV) and nano dispersion. The 
graphs display the AUC of open arm entrances (A), closed arm entrances (B), time in open arm 
(C), time in closed arm (D), time on central platform (E) and central platform latency (F). Data 
points represent mean with interquartile range. Also displayed are the results of the Mann-
Whitney U test and significance was defined as P <0.05. N= 10. 
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The number of entrances to the open arm made by the vehicle control group (9.8 
events/5mins/week [IQR 7.8-19.8]) was not significantly different from either 
the pre-clinical formulation of efavirenz (15.0 events/5mins/week [IQR 8.6-
18.1], P = 0.44) or SDN (9.3 events/5mins/week [IQR 4.5-11.0], P = 0.32) 
(Figure 3A). The conventional pre-clinical formulation of efavirenz group made 
significantly more open arm entrances than the SDN group (P = 0.04). The 
number of entrances to the closed arm made by the vehicle control group (28.8 
events/5mins/week [IQR 18.8-31.4]) was not significantly different from either 
the conventional pre-clinical formulation of efavirenz (26.0 events/5mins/week, 
[IQR 19.9-31.8], P = 0.44) or SDN (23.5 events/5mins/week [IQR 11.5-27.4], P 
= 0.22) (Figure 3B). There was no significant difference in the closed arm 
entrances between efavirenz and the SDN groups (P = 0.32). 
 
The duration of time spent on the open arm made by the vehicle control group 
(39.2 % time/5mins/week [IQR 24.8-73.5]) (Figure 3C) showed no significant 
difference in comparison with either the conventional pre-clinical formulation of 
efavirenz group (51.8 % time/5mins/week [IQR 34.2-83.6], P = 0.44) or the SDN 
group (29.2 % time/5mins/week [IQR 19.7-66.5], P = 0.44). The efavirenz group 
showed no significant difference from the SDN group (P = 0.06). There was no 
significant change in the time spent on the closed arm (Figure 3D) when 
comparing the SDN group (197.4 % time/5mins/week [IQR 153.9-276.3]) with 
the vehicle control group (184.2 % time/5mins/week [IQR 130.3-272.8], P = 
0.80. The conventional pre-clinical formulation of efavirenz group spent 
significantly less time (107.9 % time/5mins/week [IQR 87.7-152.1], on the 
closed arm than either the vehicle control (P = 0.029) or SDN (P = 0.011) 
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groups. There was no significant change in the time spent on the central platform 
(Figure 3E) when comparing the SDN group (111.8 % time/5mins/week [IQR 
112.0-201.1]) with the vehicle control group (171.7 % time/5mins/week [IQR 
91.9-190.7], P = 0.91. The conventional pre-clinical formulation of efavirenz 
group showed the inverse of the closed arm, spending increased time (212.9 % 
time/5mins/week [IQR 188.3-253.3]) on the central platform, when compared to 
the control group or the SDN group, P = 0.009 and P = 0.011, respectively. The 
central platform latency (Figure 3F) of the control group (15.0 
seconds/5mins/week [IQR 7.5-49.4]) showed no significant difference compared 
to the efavirenz (38.2 seconds/5mins/week [IQR 21.05-64.6], P=0.17) group or 
the SDN group (40.6 seconds/5mins/week [IQR 26.7-75.4], P=0.08). The 
efavirenz group showed no significant difference from the SDN group (P = 
1.00). 
 
3.3.2 Ethological measures 
In addition to collecting data on the spatial distribution of the rats, a number of 
ethological measures were recorded.  The ethological measures were divided into 
2 categories: risk-assessing behaviour (stretch attend postures, head dips and 
rearing) and behaviour-indicating sedation (instances of grooming and non-
exploratory behaviour). From these multiple behaviours 2 composite measures 
were created: risk assessment (the total number of occurrences of behaviour 
indicating assessment of the environment for potential risk factors) and sedation 
(the total duration of time spent stationary). As with the spatial measures the 
median for each group was plotted against duration of treatment (Figure 4). The 
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median AUC of each group was plotted (Figure 5) and compared for statistically 
significant differences. 
 
 
 
Figure 4 shows the ethological measures plotted against time from the EPM for vehicle control, 
conventional pre-clincial formulation of efavirenz (EFV) and nano dispersion. The graphs display 
risk assessment (A) and sedation (B). Data points represent median with interquartile range. N = 
10. 
 
The SDN group showed significantly less instances of risk-assessing behaviour 
(Figure 5A) (66.3 events/5mins/week [IQR 47.3-88.3]) when compared to the 
vehicle control (99.3 events/5mins/week [IQR 84.0-108.1]), P = 0.02. There was 
no significant difference in risk assessing behaviour when comparing the 
conventional pre-clinical formulation of efavirenz group to either the vehicle 
control or SDN groups, P = 0.35 and P = 0.09, respectively. There was no 
significant difference in sedation (Figure 5B) in the conventional pre-clinical 
formulation of efavirenz (111.2 events/5mins/week [IQR 40.3-161.3]), or SDN 
(309.7 events/5mins/week [IQR 119.5-549.3]), compared to the control (179.6 
events/5mins/week [IQR 74.5-443.9]), P = 0.14 and P = 0.44 for conventional 
pre-clinical formulation of efavirenz and SDN, respectively. There was a 
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significant increase in the SDN group compared to the conventional pre-clinical 
formulation of efavirenz group, P = 0.03. 
 
 
Figure 5 shows the AUC (for each of the measurements displayed in Figure 4) for vehicle 
control, conventional pre-clinical formulation of efavirenz (EFV) and nanodispersion. The graphs 
display the AUC of risk assessment (A) and sedation (B). Data points represent mean with 
interquartile range. Also displayed are the results of the Mann-Whitney U test and significance 
was defined as P <0.05. N= 10. 
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3.4 Discussion 
The data presented in this chapter show that following multiple doses rats treated 
with efavirenz, but not SDN efavirenz, exhibited anxiety-like behaviour in the 
EPM. Our experiment failed to fully replicate the anxiogenic effects of efavirenz 
that were previously reported in mice using the EPM (131). However, the profile 
of changes indicated some clear behavioural effects that are likely to be linked to 
drug-related CNS effects. In particular, a tendency of efavirenz to increase time 
spent on the central platform may be indicative of anxiogenesis. By contrast, the 
efavirenz SDN did not consistently affect behaviour in a manner that would 
indicate anxiogenic activity.  
 
The EPM has been used for over 20 years to investigate anxiety in rodents (136). 
Typically the EPM has been used to focus on the spatial distribution of the 
rodent over time, measuring the ratio of time spent on the open and closed arms. 
These measures assess the rodent’s natural tendency towards enclosed spaces 
and aversion towards open spaces and heights against their natural instinct to 
investigate novel environments (134). Using traditional measures anxiolytics 
(such as benzodiazepines) and anxiogenics (such as N-methyl-B-carboline-3-
carboxamine, FG 7142) will increase and decrease time spent in the open and 
closed arms respectively (137). However, over the years of usage a number of 
groups have identified additional measures of anxiety, which can be used for the 
EPM system. Time spent on the central platform is a factor that is not frequently 
reported, although there have been previous publications that associated 
increased time spent here with anxiety-like behaviour (138, 139). Additionally, 
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benzodiazepines such as nitrazepam have been shown to decrease time spent on 
the central square (137).  
 
The data presented here show no significant differences in exploration of the 
open arm in either the efavirenz or SDN groups when compared to the control 
group. Using only traditional measures these data would indicate no anxiogenesis 
in response to either treatment. However, by employing additional measures, 
subtle differences in behaviour were observed. The time spent in the closed arm 
and central platform was significantly different when comparing efavirenz to the 
control or SDN groups for the majority of the testing period. In week 2, the 
percentage of time spent on the central platform was increased in the efavirenz 
group, with an associated decrease in time spent on the closed arm, compared to 
either the SDN or control. The pattern of increased time on the central square in 
response to conventional efavirenz was also observed in weeks 3 and 4. There 
was no difference in the distribution of time spent in open arm, closed arm or 
central square in weeks 1 and 5, possibly due to efavirenz having not 
accumulated enough in the rodents to induce anxiety at week 1, and in week 5 
the rodents may have fully habituated to the EPM.  
 
A previous study used the EPM to investigate the anxiety-related behaviour and 
cognitive performance in mice following dosing with efavirenz or nevirapine. 
This study showed a clear distribution of open arm vs closed arm exploration 
(131). The behaviour was recorded following 28 days of treatment with a single 
administration of the EPM. One potential explanation why our study did not 
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show the same open:closed arm distribution may be repeat exposure to the EPM 
in our study. The data presented here were collected from 5 weekly tests. 
Efavirenz may not have accumulated enough in the rodents to induce anxiety at 
week 1 and the behaviour in each of the 4 remaining tests was likely to have 
been affected by habituation. There is evidence demonstrating that initial 
exposure to the EPM will affect the behaviour in subsequent testing. File et al 
demonstrated that benzodiazepines reduced anxiety in initial exposure to the 
EPM but on a subsequent test the same anxiolytic effect was no longer observed 
(140). The anxiety observed in our study may be more pronounced if only a 
single EPM test was applied. However, this initial study aimed to investigate the 
progression of anxiety after multiple doses.  
 
Currently, it is unknown how long the SDN efavirenz remains in vivo as 
nanoparticles or even whether intact nanoparticles enter the systemic circulation. 
However, utilising fluorescence resonance energy transfer (FRET), intact 
nanoparticles were shown to pass through Caco-2 cell monolayers in 
transcellular permeation experiments (141). These in vitro data indicate that 
paracellular transport may be possible and that intact nanoparticles may traverse 
the gut barrier in vivo. The SDNs used in this study have an average diameter of 
200nm (141). If SDNs do indeed enter the circulation, they may be too large to 
interact with the body in the same manner as solubilised efavirenz.  
 
Although the mechanisms of efavirenz CNS side effects are currently unknown, 
there is evidence implicating the hydroxylated metabolites of efavirenz (OH 
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efavirenz). In a previous study, isolated rodent hippocampal neurons were 
exposed to efavirenz, 7OH efavirenz and 8OH efavirenz. Although all 3 
produced neuronal damage, 8OH efavirenz was shown to be more toxic (142). 
8OH efavirenz has also been shown to stimulate glycolytic flux resulting in 
altered glucose metabolism, which may contribute to the CNS side effects (143). 
Efavirenz contained within the nanoparticles may be protected from metabolism 
and subsequently lead to a decrease in the formation of 8OH efavirenz in 
comparison to conventional formulation. Indeed, this hypothesis would may also 
explain the higher pharmacokinetic exposure observed previously when dosed 
orally to rats (97) 
 
Other potential mechanisms of CNS toxicity involve interactions of efavirenz 
with neurotransmitters and the associated receptors (discussed in sections 2.1 and 
2.4). Behavioural analysis of rats treated with efavirenz revealed behaviour 
associated with modulation of the 5-HT2A (127). If intact SDNs are present 
within the circulation and pass the BBB, the size of the SDNs may preclude 
interaction with the receptor where free efavirenz may be able to interact and 
modulate neuronal signalling via 5-HT2A receptor. 
 
We interpret these results as indicating that the nanoformulation of efavirenz 
may have reduced potential to induce neurocognitive disturbance, either acutely 
or following chronic administration. 
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Enhanced single dose pharmacokinetics of this formulation has previously been 
shown, but the limitation of the current project was that steady state 
pharmacokinetics was not assessed during the behavioural analysis. Previous 
studies have demonstrated an association with increased plasma exposure in 
humans and the occurrence of CNS toxicity (74). Pharmacokinetics data in 
plasma and brain tissue paired with the behavioural data presented here will 
provide a better indication of the effects of nanoformulation on the efavirenz 
associated CNS toxicities. 
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Chapter 4 
 
Liquid Chromatography Tandem Mass Spectrometry Method 
for Quantification of Efavirenz in Plasma, Brain and Cell 
Culture Medium  
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4.1 Introduction 
The work presented in the remainder of this thesis required the development of a 
liquid chromatography tandem mass spectrometer (LC-MS/MS) bio-analytical 
method. This chapter discusses the optimisation of the detection and 
quantification of efavirenz using lopinavir as internal standard (IS). The assay 
presented here was developed and validated in accordance with FDA guidelines 
(144). Criteria such as linearity, accuracy (the degree of variation from known 
value, assessed by controls [QCs]), precision (the degree of variation within 
repeated measurements), selectivity (ensuring detection of the analyte and not an 
endogenous compound within the sample matrix) and recovery (determining the 
percentage of recovery and more importantly the reproducibility of the extraction 
process) were all assessed.  
 
Efavirenz was first licensed for the treatment of HIV in 1998, since then multiple 
methods for detection in plasma have been developed for LC-MS/MS. Many of 
the methods developed have been utilised to assess association with efavirenz 
plasma concentrations and CNS toxicity or polymorphisms in key proteins 
influencing efavirenz disposition (72, 74). Some recently published methods 
show linearity with lower limit of quantification ranging from 20ng/ml to 
300pg/ml (145, 146). 
 
Despite the major focus being on the concentrations of efavirenz in plasma, other 
matrices have also been investigated such as recent work on breast milk. 
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Currently, the WHO recommends “on demand” breast-feeding for new born 
(147). This presents a unique difficulty as mothers receiving antiretroviral 
therapy are at risk of introducing antiretroviral agents to their children via breast 
milk. To assess this Olagunju et al have recently developed a novel LC-MS/MS 
method for detection of efavirenz in dried breast milk spots (147). The assay was 
linear from 50ng/ml to 7500ng/ml. Accuracy and precision ranged between 
95.2% and 102.5%, 1.05% and 9.53%, respectively. Extraction from dried breast 
milk spots showed excellent recovery, methanol extraction yielded an average 
recovery of 106.4%. 
 
As discussed previously in section 1.4.1, efavirenz CNS toxicity has been 
associated with high plasma concentrations. One of the limitations with such 
analyses is plasma concentrations of efavirenz do not necessarily correlate with 
concentrations in CSF and brain tissue. To investigate CNS concentrations of 
efavirenz, multiple LC-MS/MS methods have been developed to analyse 
efavirenz concentrations in CSF (50, 57, 148). An example of these methods 
achieved linearity over the range of 1.1ng/ml to 51ng/ml (50). Accuracy and 
precision were reported to exhibit <10% variability with >80% recovery. 
Although assessing CSF is a step towards understanding efavirenz concentrations 
in the CNS, CSF and brain tissue concentrations of drugs may vary wildly and 
may not represent the disposition of efavirenz in the CNS per se (as discussed in 
section 1.4). 
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Recently, an LC-MS/MS method was developed to analyse efavirenz 
concentrations in homogenised tissue from macaques, following orally 
administered efavirenz. The assay demonstrated linearity over the range of 
200pg/ml to 20ng/ml. The authors assessed efavirenz concentrations in HIV 
sanctuary sites (discussed in section 1.5), in particular the brain, lymph nodes 
and GI tract. The data presented showed efavirenz accumulated in tissue when 
compared to plasma (~3 fold higher than plasma in the GI tract and ~2 fold 
higher than plasma in lymph nodes) or CSF (>6 fold greater than CSF) (149). 
 
The work presented in this thesis required the detection of efavirenz in multiple 
matrices. Therefore, an assay was optimised for efavirenz from plasma and then 
the performance of the assay was assessed in cell culture medium, phosphate 
buffered saline (PBS), and brain tissue homogenate. A major concern was the 
interference from endogenous analytes within the non-plasma matrices that may 
have been present at a lower concentration or absent from plasma. The aim of 
this chapter was the development of a rapid, sensitive and replicable assay for the 
detection of efavirenz in multiple matrices. 
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4.2 Methods and Materials 
 
4.2.1 Materials 
Efavirenz powder (>98% pure) was purchased from LGM Pharma inc (Boca 
Raton, USA). Lopinavir powder (>98% pure) was purchased from LGC Pharma 
(London, UK). All other consumables were purchased from Sigma Aldrich 
(Dorset, UK). 
 
4.2.2 Tuning for Efavirenz and Internal Standard 
Detection of efavirenz and lopinavir was conducted using a TSQ endura LC-
MS/MS (Thermo scientific). Tuning was performed using direct infusion 
(20µl/min) of a 500ng/ml stock of efavirenz with 50% mobile phase A (100% 
H2O [LC-MS/MS grade] 5mm ammonium formate), 50% mobile phase B (100% 
acetonitrile [ACN] 5mm ammonium formate) at a flow rate of 300µl/min. 
Ionisation was achieved via heated electron spray ionization in negative mode. 
The following parameters were optimised to achieve the highest signal intensity 
for efavirenz spray voltage, sheath gas and auxiliary gas. The IS was then 
directly injected (500ng/ml) to ensure detection using the optimised efavirenz 
settings. Following optimization for the parent mass of efavirenz (315) and IS 
(628), selected reaction monitoring (SRM) scan was utilised for detection of the 
break down products. 
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4.2.3 Chromatographic Separation 
The chromatographic separation was achieved using a multi-step gradient with a 
Hypersil gold C-18 column (Thermo scientific; Table 1). The assay was 
conducted over 8 minutes at a flow rate of 300µl/min. 
 
Time (mins) Mobile Phase A (%) Mobile Phase B (%) 
0.0 90 10 
0.1 90 10 
0.5 14 86 
5.0 8 92 
5.1 3 97 
6.0 3 97 
6.0 90 10 
8.0 90  10 
 
Table 1 shows the chromatographic conditions for the detection of efavirenz and IS. 
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4.2.4 Extraction from Plasma and Cell Culture Medium and PBS 
One hundred µl of sample (20% ACN was added to both cell culture medium and 
PBS to aid efavirenz dissolution in these matrices) were diluted with ACN 
(sample: ACN ratio 1:4) and thoroughly vortexed. Samples were then 
centrifuged at 4000g for 10 minutes at 4°C. The supernatant fraction was 
transferred to a fresh glass vial and evaporated, samples were placed in a rotary 
vacuum centrifuge at 30°C and then reconstituted in 140µl of H2O:ACN (60:40). 
100µl of the sample was then transferred into 200µl chromatography vials. 5µl of 
each sample was injected for analysis.  
 
4.2.5 Extraction from Brain Tissue 
Male Wistar rats (Charles River, UK) weighing 180 – 220g on arrival were 
sacrificed using an appropriate schedule 1 method. Following termination brain 
was extracted and stored at -80˚C. (150). Rat brain tissue was then homogenised 
in 3 volumes (W:V) of plasma. Extraction was performed using protein 
precipitation detailed in the previous section. 
 
4.2.6 Assay Validation 
The assay was validated according to the most recent FDA guidelines (144). The 
following criteria were assessed: linearity, recovery, specificity, accuracy, 
precision, inter-assay and intra-assay variability. 
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Linearity 
A calibration curve of efavirenz was prepared in plasma via serial dilution, 
ranging from 1.9ng/ml to 500ng/ml. Extraction was performed using protein 
precipitation. Linearity was assessed by 3 independent preparations of the 
standard curve. Maximum allowed deviation of standards was set at 15% of the 
stated value, excluding the lower limit of quantification where deviation was set 
at no more than 20%. 
 
Recovery 
Recovery experiments were performed by comparing the results for extracted 
samples of efavirenz at three concentrations (20ng/ml, 100ng/ml and 400ng/ml) 
with non-extracted standards that were taken to represent 100% recovery.  
 
Specificity 
The degree of interference from the matrix (due to potential interfering 
substances including endogenous matrix components, metabolites and 
decomposition products) was assessed via comparison of extracted blank 
samples with the lowest point of the standard curve (lower limit of 
quantification). The lower limit of quantification was a minimum of 5 times 
greater than the background signal. 
 
 
 95 
Accuracy and Precision 
The accuracy of an analytical method describes the closeness of mean test results 
obtained by the method to the actual value (concentration) of the analyte. 
Accuracy was assessed by preparation of three concentrations (in the range of the 
standard curve 20ng/ml, 100ng/ml and 400ng/ml) with each preparation in 
triplicate. The mean value of each concentration should be within 15% of the 
stated concentration (except the lower concentration, where deviation should be 
less than 20%). Accuracy was calculated using the following formula: 
% 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = 𝑒𝑟𝑟𝑜𝑟𝑠𝑡𝑎𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒  𝑥 100 
The precision of an analytical method describes the closeness of individual 
measures of an analyte when the procedure is applied repeatedly to multiple 
aliquots of a single volume of biological matrix. Precision of the assay was 
determined by preparation of three concentrations (in the range of the standard 
curve 20ng/ml, 100ng/ml and 400ng/ml) with each preparation in triplicate. The 
mean value of each concentration should be within 15% of the stated 
concentration (except the lower concentration, where deviation should be less 
than 20%). Precision was calculated using the following formula: 
% 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛𝑚𝑒𝑎𝑛 𝑎𝑠𝑠𝑎𝑦 𝑣𝑎𝑙𝑢𝑒  𝑥 100 
Accuracy and precision were assessed for intra and inter assay variability. The 
standard curve and QCs were prepared in triplicate and analysed 3 times. 
Variance in accuracy and precision should not vary within 15% of the stated 
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concentration (except the lower concentration, where deviation should be less 
than 20%) within a single assay or between repetitions of the assay (144). 
 
4.2.7 Statistics 
Data were assessed for normality using the Shapiro Wilk test. Statistical analysis 
was performed by unpaired T test and significance was defined as P <0.05. All 
data are given as mean with standard deviation. 
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4.3 Results 
 
4.3.1 Tuning Settings 
The aim of optimising the tuning settings was firstly to maximise the detection of 
efavirenz and secondly to ensure detection of the IS. Table 2 shows the finalised 
settings.  
 
Parameter Optimised Setting 
Negative Ion (V) 2700 
Sheath Gas 35 
Aux Gas 15 
Sweep Gas 0 
 
Table 2 shows the optimised tuning settings for the detection of the parent 
compounds of efavirenz and IS. 
 
In addition to detecting the parent molecule, the detection of the product ions of 
each compound was also optimised. By searching for both the parent and product 
ions, sensitivity and specificity are increased. This is particularly advantageous 
when analytes are contained in complex matrices such as plasma (151). Table 3 
shows the product ions produced during the selected reaction monitoring scan for 
efavirenz and IS. 
 
 98 
Compound Precursor  (m/z) Product (m/z) Collision Energy (V) 
  242.1 16.5 
Efavirenz 315 244.0 17.0 
  250.0 17.0 
  121.2 33.5 
Lopinavir 627 178.1 26.5 
  198.1 22.5 
 
Table 3 shows the parent mass, product ion and the collision energy for efavirenz and IS. 
 
4.3.2 Extraction Efficiency from Plasma, Brain Tissue and Cell 
Culture Medium 
The recovery was measured at three QC concentrations (Figure 1). The mean 
recovery (across all 3 QCs) from plasma, brain tissue, EBM-2 medium and PBS 
were 95% (standard deviation 8.9), 91% (standard deviation 7.8), 59% (standard 
deviation 6.1) and 84% (standard deviation 11.6), respectively. When compared 
to plasma, there were no statistically significant differences in recovery from 
brain tissue, or PBS at the low and medium QCs. The high QC was significantly 
lower for both brain tissue (90.72%, P = 0.01) and PBS (77.84%, P = 0.001) 
Recovery from the EBM-2 medium was significantly lower at all the QCs (low 
QC 60.06% P = 0.001, medium QC 53.24% P = 0.004 and high QC 64.98% P = 
0.002). 
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Figure 1 shows the percentage recovery for the low (a), medium (b) and high (c) QCs in 
extracted plasma, extracted brain tissue, EBM-2 medium (complete media is described in section 
5.2.2) and PBS. Data is show percentage of unextracted standards. 
 
4.3.3 Assay Validation 
 
Linearity 
Standards extracted from plasma showed good linearity (R2 = 0.992). The peak 
area ratio (analyte to IS; variation of IS was less than 15% in each run) was 
proportional to the stated concentrations over the range of 500ng/ml to 1.9ng/ml. 
Figure 2 shows a representative calibration curve. Calibration curve was 
generated using a quadratic equation with a weighting of 1/X. 
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Figure 2 shows the standard curve generated from extracted plasma 
standards of efavirenz over the range of 500ng/ml to 1.9ng/ml. 
 
Specificity 
The matrix effect of plasma was examined by comparing extracted blank plasma 
to extracted plasma spiked with 1.9ng/ml of efavirenz. Figure 3a shows the 
chromatogram produced by the extracted blank. There is a visible peak (area of 
134) at the retention time of efavirenz (3.7 minutes). FDA guidelines require the 
lower limit of quantification produce a peak area of at least five-fold greater than 
that observed in the blank matrix. Figure 3b shows the peak produced from the 
lower limit of quantification (1.9ng/ml). The peak area is 1491, which complies 
with FDA guidelines. Figure 3c shows the peak produced by the upper limit of 
quantification (500ng/ml). 
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Accuracy and Precision 
 
The accuracy and precision for each individual run at 3 QC levels (low 
(20ng/ml), medium (100ng/ml) and high (400ng/ml) is shown in table 4. The 
percentage error of accuracy fell below 15% for each of the 3 repeats (1 varied 
between -0.25% and -11.45%, 2 varied between 0.01% and -6.32%, 3 varied 
between 0.78% and -4.66%). The percentage error of precision also fell below 
15% for each of the 3 repeats (1 varied between -5.52% and 11.05%, 2 varied 
between 2.93% and 5.66%, 3 varied between 1.25% and 3.78%).  
 
Inter-assay Variability 
The variability between assays was calculated to demonstrate that the assay 
maintained accuracy and precision across repetitions of the assay. Table 5 shows 
the variance of accuracy and precision calculated from the mean values of the 3 
repetitions of the assay. The percentage error in accuracy fell below 15% across 
all 3 repeats (range between -0.52% and -6.34). Percentage variance of precision 
also fell below 15% across all 3 repeats (range between 1.48% and 5.61%). 
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 Average 
(ng/ml) 
Standard 
Deviation 
Variance of 
Accuracy 
(%) 
Variance of 
Precision 
(%) 
Low  
(20ng/ml) 
19.90 0.29 -0.52 1.48 
Medium 
(100ng/ml) 
94.91 5.33 -5.09 5.61 
High  
(400ng/ml) 
374.63 20.38 -6.34 5.44 
 
Table 5 shows the accuracy and precision of 3 repetitions of the assay. Accuracy and 
precision were assessed in triplicate of 3 QCs (low [20ng/ml], medium [100ng/ml] and high 
[400ng/ml]). 
 
 105 
4.4 Discussion 
The assay presented here represents a simple, robust and sensitive LC-MS/MS 
assay. In addition to accurate and precise quantification in plasma this assay has 
been shown to be versatile allowing quantification in brain tissue homogenate, 
EBM-2 culture medium and PBS. The assay was fully validated in plasma. As 
the change in matrix represents a minor change to the assay only partial 
validation for the change of matrices was required, in accordance with FDA 
guidelines (144).  
 
Primary validation was conducted in plasma satisfying FDA bioanalytical 
method development guidelines, demonstrating good accuracy, precision and 
linearity. Although full validation for different matrices is not required, matrix 
effects must be assessed for each matrix. The change in matrix may potentially 
affect the behaviour of the assay significantly. Brain tissue homogenate and cell 
culture medium both contain different quantities of protein compared to plasma. 
As efavirenz is highly protein bound (99% in plasma) and poorly water soluble 
(<10µg/ml), the change in matrix has the potential to alter efavirenz recovery 
(97, 105). As the change in matrix is considered a minor change, partial 
validation was acceptable. Partial validation required the determination of intra 
assay variability in accuracy and precision (152). These data demonstrate the 
versatility and reliability of the assay presented here. 
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The sensitivity of the assay developed here is of a comparable standard to recent 
publications. Some of the newer assays surpass the sensitivity here, 200pg/ml in 
brain tissue and 300pg/ml in plasma (145, 149). The greatest advantage of the 
assay developed in this chapter is the ability to assess efavirenz in multiple 
matrices. It should also be noted that the assay was developed to assess a range 
of concentrations not predicted to be lower than 10ng/ml. Given the low signal 
produced by blanks, the lower limit of detection had not been established. The 
true limit of the assay is potentially much lower than the range validated here. 
 
One significant improvement would be to include the major metabolites of 
efavirenz, 8OH efavirenz and 7OH efavirenz. Recent publications have 
demonstrated, in vitro, a higher cytotoxicity of 8OH efavirenz compared to the 
parent compound (as discussed in section 3.4). LC-MS/MS methods have been 
developed to examine efavirenz and its metabolites in CSF (153). The authors 
investigated dose reduction of efavirenz (600mg once daily to 400mg once daily) 
and demonstrated 8OH efavirenz concentrations in CSF did not appear to be 
dependant on plasma concentrations of efavirenz. The assay presented in this 
chapter could potentially be modified to include 8OH efavirenz and 7OH 
efavirenz and also optimised for use in CSF. The added advantage would be to 
analyse concentrations in brain tissue allowing a more complete description of 
the distribution of efavirenz and its metabolites in the CNS. However, these 
additional features were not a prerequisite for progression of the research in this 
thesis so further optimisation was unnecessary. 
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This chapter details the optimization of a robust, simple and sensitive LC-
MS/MS assay. The final assay conformed to FDA bioanalytical development 
guidelines and was capable of assessing efavirenz in multiple matrices. Although 
the assay satisfied the requirements for its application in subsequent chapters, the 
assay could be modified to suit additional requirements as discussed.  
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Chapter 5 
 
In vitro Characterisation of solid drug nanoparticle compositions 
of efavirenz in the hCMEC/D3 cell line 
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5.1 Introduction 
The data generated in chapter 3 indicated reduction in anxiety in response to the 
SDN formulation, in comparison to a conventional pre-clinical formulation of 
efavirenz. Currently, it is unknown if and how long intact particles survive in the 
circulation. However, some published in vitro data indicate the possibility of 
SDNs entering the circulation. Using SDNs composed of FRET dyes, co-
localisation of both dyes demonstrated that intact particles were able to traverse a 
Caco-2 monolayer in a transwell system (141). If intact particles enter the 
systemic circulation, differential passage across the BBB may contribute to the 
observations in chapter 3. 
 
The BBB is highly effective at preventing the entry of antiretrovirals to the brain, 
as discussed in section 1.4. One of the major obstacles presented by the BBB, is 
the presence of multiple transport proteins covering a wide array of substrates. 
Many xenobiotics are substrates for one or more drug transporters, limiting or 
even completely preventing entry to the brain.  
 
The interactions of efavirenz with transporters are not thoroughly characterised. 
One of the most clinically important transporters is P-gp (154). P-gp has been 
demonstrated to significantly impact the pharmacokinetics of numerous drugs 
(154). P-gp performs adenosine triphosphate (ATP)-dependent efflux from cells 
and it is expressed in many excretory and barrier tissues (155). In humans, P-gp 
is encoded by ABCB1 and is expressed in liver, kidney, adrenal gland, intestine, 
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BBB, placenta, blood–testis and blood–ovarian barriers (155). Although there 
have been genetic associations with efavirenz concentrations, in vitro evidence 
demonstrates efavirenz is not a substrate for P-gp (156, 157). However, there is 
some evidence that efavirenz may be a substrate for BCRP (ABCG2). Inhibition 
of BCRP in an ex vivo model showed increased mucosal to serosal permeation of 
efavirenz in everted gut sacs (158). Efavirenz may also be a substrate for one or 
more of solute carrier organic anion transporters (SLCO) transporters. The 
cellular accumulation of efavirenz was reduced by montelukast and estrone-3-
sulphate, suggesting inhibition of a SLCO transporter (157). The effects of 
montelukast may be via inhibition of other transporters, as efavirenz has 
previously been shown not to be a substrate of the major SLCO transporters 
(SLCO1A2, SLCO1B1 or SLCO1B3) (159, 160). The interactions of efavirenz 
and drug transporters have not been fully described, as determination of the 
substrate kinetics have not been conducted.  
  
One of the potential benefits of nanoformulation is that due to their size, 
nanoparticles are unlikely to interact with drug transporters. This has been 
demonstrated in vitro with doxorubicin nanoparticles and BCRP (161). Although 
the size of a nanoparticle may preclude interactions with transport proteins, other 
methods of cellular uptake may begin to affect the disposition of nanoscale 
formulations. Endocytosis is an umbrella term to describe the multiple 
mechanisms (including clatharin-mediated endocytosis, calveolae-mediated 
endocytosis and macropinocytosis) mammalian cells have developed for the 
uptake of molecules from the extracellular environment (162). Nanoparticle 
characteristics have been demonstrated to influence the mechanisms of 
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endocytotic uptake (such as surface chemistry, shape and size). For example, size 
has been demonstrated to play an important role in which mechanism is 
activated. Macropinocytosis is typically used in larger particle sizes (<2µM), 
whereas clatharin-mediated (<300nm) and caveolae-mediated (<80nm) 
endocytosis are activated by smaller particles (163). Therefore, the mechanism of 
uptake may play an influential role in determining the intracellular fate of 
nanoparticles (164).  
 
Differential uptake of efavirenz and SDN formulated efavirenz may affect the in 
vivo CNS distribution and toxicity. In order to investigate the in vitro 
mechanisms of uptake, the hCMEC/D3 cell line was used in uptake and 
inhibition studies. The hCMEC/D3 is an immortalised cell line derived from 
human microvascular brain endothelial cells. The aim of this chapter was to 
investigate the mechanisms of uptake of conventional pre-clinical and SDN 
formulations of efavirenz in vitro utilising the hCMEC/D3 cell line. As reduced 
anxiety was observed in chapter 3 and increased in vivo pharmacokinetics have 
been previously reported, we aimed to determine if different mechanisms of 
uptake may contribute to the observations (97). 
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5.2 Methods 
 
5.2.1 Materials 
EBM-2 medium was purchased from Lonza (Slough, UK), Penicillin-
Streptomycin, Chemically Defined Lipid Concentrate and HEPES were 
purchased from Invitrogen (Paisley, UK). Fetal Bovine Serum (FBS) gold were 
purchased from PAA, the Cell Culture Company (Cambridge, UK). The 
hCMEC/D3 cell line was a kind gift from Pierre-Olivier Couraud, (INSERM, 
Paris, France). All other consumables were purchased from Sigma Aldrich 
(Dorset, UK). 
 
5.2.2 hCMEC/D3 culture 
hCMEC/D3 were cultured in EBM-2 medium supplemented with FBS gold 5%, 
penicillin-streptomycin 1%, hydrocortisone 1.4µM, ascorbic acid 5µg/ml, 
Chemically Defined Lipid Concentrate 1/100, HEPES 10mM and bFGF 1ng/mL. 
All culture flasks and plates were coated with rat collagen type 1 for 1 hour prior 
to use. Cells were cultured at 37°C in 5% CO2. Cells ere passaged every 3-4 days 
when confluent. 
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5.2.3 MTT Assay 
Cells were seeded on a pre-collagenated 96-well plate at 100µl of 1x105 cells/ml. 
The plates were then incubated for 24 hours at 37°C in 5% CO2 to allow cell 
adherence. Following incubation, the medium was replaced with 100 µl of fresh 
medium containing the drug at desired concentrations. Positive and negative 
controls were represented by no cells (representing 100% cell death) and by cells 
cultured in the presence of a vehicle control (representing 100% cell viability), 
respectively. Following 1 hour incubation with the drug, the medium was 
removed and replaced by 20 µl of MTT reagent (5 mg/ml solution 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in Hanks balanced salt 
solution [HBSS]). The cells were incubated for 2 hours in the MTT reagent. 
Following incubation, 100 uL of lysis buffer (50% N-N-dimethylformamide in 
water containing 20% sodium dodecyl sulfate, 2.5% glacial acetic acid and 2.5% 
HCl, pH 4.7) was added to each well. Cells were then incubated overnight at 
37°C in 5% CO2 to allow complete cell lysis. Following incubation, the 
absorbance of each well was monitored using a TECAN GENios plate reader, 
with filters set to 560 nm.  
 
5.2.4 The Effects of Inhibitors of Drug Transporters on 
Efavirenz Accumulation 
Cells were seeded on pre-collagenated 6 well plates at a density of 2x106/ml and 
allowed to adhere overnight. Medium was aspirated and replaced with 1ml fresh 
medium containing 10µM (0.014µCi) of conventional pre-clinical formulation of 
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efavirenz or efavirenz SDNs (in the presence or absence of transporter inhibitors, 
Table 1). Cells were incubated at 37°C in 5% CO2 in the presence of the drugs 
for 1 hour. Following incubation, 100µl of medium was aspirated and added to 
scint vials with 4ml goldstar scintillation fluid (extra cellular drug content). Cells 
were then washed 3 times with ice-cold HBSS. Following washes, 1ml of trypsin 
was added to the cells and then incubated at 37°C in 5% CO2 for 15 minutes. The 
trypsin was then aspirated and added to scint vials with 4ml goldstar scintillation 
fluid (intracellular content).  
 
Cellular accumulation ratios were calculated using the following formula (where 
DPM = disintegrations per minute): 
𝐶𝐴𝑅 = (𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝐷𝑃𝑀/𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑙𝑢𝑚𝑒)(𝑒𝑥𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝐷𝑃𝑀/𝑒𝑥𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑣𝑜𝑙𝑢𝑚𝑒) 
Cellular volumes were determined using the ScepterTM cell counter 2.0 (Merck 
Millipore, Billerica USA). Cell volumes were taken from a mean of 3 replicates, 
hCMEC/D3 volume 2.27pl. 
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Inhibitor Known to inhibit Concentration 
used (µM) 
Reference 
Verapamil ABCB1, organic cation transporter 
(OCT) 1 
50 (165) 
Probenecid ABCC1, BCRP, multidrug 
resistance proteins (MRPs), organic 
anion transporter (OATs) 
50 (166) 
Prazosin OCT1 and OCT3 50 (165, 
167) 
Montelukast ABCC2, organic anion-
transporting polypeptide (OATP) 
1B3 OATP2B1 
50 (157) 
Amantadine OCT1 and OCT2 100 (165) 
Cyclosporine 
A 
SLCO1B1, BCRP 10 (168) 
Naringin OATP1A2 50 (169) 
Corticosterone OCT3, SLCO1B1 10 (165) 
 
Table 1 shows transport protein inhibitors used. Also shown are the transporters known to be 
inhibited and references. 
 
5.2.5 The Effects of Inhibitors of Endocytosis on Efavirenz 
Accumulation 
Cells were seeded on pre-collagenated 6 well plates at a density of 2x106/ml and 
allowed to adhere overnight. Medium was aspirated and replaced with 1ml fresh 
medium containing dynasore (100µM), indomethacin (100µM) or cytochalasin B 
(5µM) and incubated for 30 minutes at 37°C, 5% CO2. The mechanisms of 
action of these inhibitors are detailed in table 2. Following incubation, the 
medium was aspirated and replaced with fresh medium containing 10µM of 
conventional pre-clinical formulation or efavirenz SDNs. Cells were incubated at 
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37°C in 5% CO2 in the presence of the drugs for 1 hour. Following 1 hour 
incubation, 1ml of medium was aspirated and added to 1.5ml Eppendorf tubes 
(extra cellular content). Cells were then washed 3 times with ice-cold HBSS. 
Following washes, 1ml of trypsin was added to the cells then incubated at 37°C 
in 5% CO2 for 15 minutes. The trypsin was then aspirated and added to 1.5ml 
Eppendorf tubes (intracellular content). Samples were stored at -80°C until 
analysis via LC-MS/MS (detailed in chapter 4). 
Cellular accumulation ratios were calculated using the following formula: 
𝐶𝐴𝑅 = (𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)(𝑒𝑥𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛) 
Cellular volumes were determined using the ScepterTM cell counter 2.0 (Merck 
Millipore, Billerica USA). Cell volumes were taken from a mean of 3 replicates, 
hCMEC/D3 volume 2.27pl. 
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Inhibitor Known to inhibit Concentration 
used (µM) 
Reference 
Dynasore Clatharin-dependent endocytosis 100 (170) 
Indomethacin Calveoli-dependent endocytosis 100 (171) 
Cytochalasin 
B 
Actin-dependent mechanisms 
(including macropinocytosis and 
phagocytosis) 
5 (172, 173) 
 
Table 2 shows endocytosis inhibitors used. Also shown are the mechanisms known to be 
inhibited and references. 
 
5.2.6 The Effects of Inhibitors of Endocytosis on Nanoparticle 
Uptake 
In addition to investigating the effect of endocytosis inhibitors on intra-cellular 
efavirenz concentrations, we also aimed to investigate the uptake of SDN 
particles. Recently, Liptrott et al developed a flow cytometric method to 
investigate the protein binding characteristics of SDNs. In order facilitate 
detection, 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodi-carbocyanine perchlorate 
(DiD) was incorporated into the SDNs. This method was adapted to investigate 
the uptake of DiD labeled SDNs. 
 
Cells were seeded on pre-collagenated 6 well plates at a density of 2x106/ml and 
allowed to adhere overnight. Medium was aspirated and replaced with 1ml fresh 
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medium containing dynasore (100µM), indomethacin (100µM) or cytochalasin B 
(5µM) and incubated for 30 minutes. Following incubation, medium was 
aspirated and replaced with fresh medium containing 10µM of SDN formulated 
efavirenz containing 1% DiD or dissolved SDN DiD particles (dissolved in 50% 
H2O and 50% MeOH). The DiD labeled SDNs were made as described in section 
3.2.3 with the exception of 69% efavirenz and 1% DiD replacing 70% efavirenz 
(174). Cells were incubated at 37°C in 5% CO2 in the presence of the drugs for 1 
hour. Following 1 hour incubation, medium was aspirated and cells were then 
washed 3 times with ice-cold HBSS. Following washes, 1ml of trypsin was 
added to the cells, then incubated at 37°C in 5% CO2 for 15 minutes. The cells 
were then aspirated and transferred to 1.5ml Eppendorf tubes. Samples were then 
centrifuged at 2000rpm for 5 minutes at 10°C. The trypsin was aspirated and the 
cell pellet was re-suspended in 500µl of Macs buffer for analysis by flow 
cytometer. 
 
5.2.7 Statistics 
All data were assessed for normality using the Shapiro-Wilk test. Statistical 
analysis was performed by unpaired t test or Mann-Whitney U test and 
significance was defined as P <0.05 (calculated in SPSS v21). All data are given 
as mean with standard deviation. IC50 values were calculated in Prism v6.0. 
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5.3 Results 
 
5.3.1 MTT 
Prior to accumulation studies, it was necessary to determine the concentrations of 
efavirenz, SDN efavirenz and the various inhibitors that did not affect cell 
viability. To assess the cellular toxicity of the compounds used in accumulation 
studies, a concentration range of each drug was assessed using the MTT assay. 
The MTT assay is a colorimetric assay measuring the conversion of tetrazolium 
dye (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) to formazan 
(measured by increased absorbance at a wavelength of 560nm). The assay is 
frequently used as a marker of cellular toxicity, as the more cells present, the 
more metabolic activity is observed (97, 175). 
 
Figure 1 shows the MTT results for the conventional pre-clinical formulation 
(1A) (1B) and the SDN formulation of efavirenz over the range of 0.19µM to 
100µM. The IC50 values were 66.8µM (SD 21.3µM) and 57.6µM (SD 6.0µM) 
for the conventional pre-clinical formulation and SDN formulation of efavirenz, 
respectively. There was no statistically significant difference observed in IC50, P 
= 0.49. 
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Figure 1 shows the toxicity data produced by MTT for efavirenz (A) and SDN efavirenz (B). 
Data points represent mean (± SD), N = 4. Also shown is the sigmoidal dose response curve 
fitted to calculate IC50. 
 
Figure 2 shows the MTT data for the inhibitors of transport proteins (amantadine 
[A], probenecid [B], verapamil [C], naringin [D], corticosterone [E], montelukast 
[F], prazosin [G] and cyclosporine A [H]) over the range of 0.98µM to 500µM. 
The IC50 could not be fitted for amantadine, probenecid, verapamil, naringin, 
corticosterone, montelukast and cyclosporine A as toxicity was not observed at 
this time point. The IC50 of prazosin was shown to be 142.5µM (SD 7.1µM). 
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Figure 2 shows the toxicity data produced by MTT for amantadine (A), probenecid (B), 
verapamil (C), naringin (D), corticosterone (E), montelukast (F), prazosin (G) and cyclosporine A 
(H). Data points represent mean (± SD), N = 4. Also shown is the sigmoidal dose response curve 
fitted to calculate IC50. 
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Figure 3 shows the MTT data for the inhibitors of endocytosis (dynasore [A], 
indomethacin [B] and cytochalasin B [C]) over the range of 0.39µM to 200µM. 
The IC50 could not be fitted for dynasore and indomethacin, as toxicity was not 
observed at this time point. The IC50 of cytochalasin B was shown to be 12.1µM 
(SD 5.1µM). 
 
 
Figure 3 shows the toxicity data produced by MTT for dynasore (A), indomethacin (B) and 
cytochalasin B (C). Data points represent mean (± SD), N = 4. Also shown is the sigmoidal dose 
response curve fitted to calculate IC50. 
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5.3.2 The Effects of Inhibitors of Drug Transporters on 
Efavirenz Accumulation 
Cellular accumulation studies were performed in the hCMEC/D3 cell line, in 
order to probe the interactions of conventional pre-clinical and SDN formulated 
efavirenz at the BBB. A panel of transporter inhibitors (Table 1) was employed 
to probe potential interactions of conventional pre-clinical or SDN formulated 
efavirenz (Figure 4).  
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Figure 4 shows the cellular accumulation ratios generated for efavirenz (A and C) and SDN 
efavirenz (B and D). Also shown are the cellular accumulation ratios in the presence of 
verapamil, probenecid, prazosin, montelukast (A and B), amantadine, cyclosporine A, naringin 
and corticosterone (C and D). Data points indicate mean (± SD), N = 4. 
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The screen of transporter inhibitors demonstrated no effect on the accumulation 
ratio of the conventional pre-clinical formulation of efavirenz (Table 3) when in 
the presence of verapamil (CAR 51.08 ±8.1, P = 0.062), probenecid (CAR 59.68 
±6.26, P = 0.485), cyclosporine A (CAR 70.25 ±27.7, P = 0.512) naringin (CAR 
89.63 ±8.13, P = 0.179) and corticosterone (CAR 80.84 ±12.54, P = 0.957). The 
accumulation ratio was significantly reduced in the presence of montelukast 
(CAR 42.91 ±2.70, P = 0.001) and amantadine (CAR 64.69 ±5.95, P = 0.027). 
The accumulation ratio of efavirenz was also reduced in the presence of prazosin, 
trending towards statistical significance (CAR 53.09 ±5.06, P = 0.054). 
 
The accumulation ratio of the SDN formulation of efavirenz was not affected by 
the presence of amantadine (CAR 91.89 ±22.70, P = 0.396), cyclosporine A 
(CAR 73.10 ±17.2, P = 0.404), naringin (CAR 89.05 ±15.74, P = 0.384) or 
corticosterone (CAR 77.23 ±12.16, P = 0.574). The accumulation ratio (Table 4) 
was significantly increased in the presence of verapamil (CAR 50.65 ±5.89, P = 
0.009), probenecid (CAR 61.22 ±12.62, P = 0.011), prazosin (CAR 54.29 ±8.08, 
P = 0.009) and montelukast (CAR 45.89 ±5.95, P = 0.050). 
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Condition Efavirenz SDN Efavirenz 
Vehicle Control 63.1 (6.61) 37.4 (3.71) 
Verapamil 51.1 (8.10) 50.7 (5.91) 
Probenecid 59.7 (6.31) 61.2 (12.62) 
Prazosin 53.1 (5.12) 54.3 (8.10) 
Montelukast 42.9 (2.31) 45.9 (6.10) 
 
Table 3 shows the cellular accumulation ratios generated for efavirenz and SDN efavirenz. Also 
shown are the cellular accumulation ratios in the presence of verapamil, probenecid, prazosin, 
montelukast. Data points indicate mean (± SD), N = 4. 
 
Condition Efavirenz CAR SDN Efavirenz CAR 
Vehicle Control 80.4 (9.02) 81.2 (6.10) 
Amantadine 64.69 (6.10) 91.9 (22.70) 
Cyclosporine A 70.3 (27.70) 73.1 (17.20) 
Naringin 89.6 (8.13) 89.1 (15.74) 
Corticosterone 80.8 (12.54) 77.2 (12.16) 
 
Table 4 shows the cellular accumulation ratios generated for efavirenz and SDN efavirenz. Also 
shown are the cellular accumulation ratios in the presence of amantadine, cyclosporine A, 
naringin and corticosterone. Data points indicate mean (± SD), N = 4. 
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5.3.3 The Effects of Inhibitors of Endocytosis on Efavirenz 
Accumulation 
In addition to transport proteins, endocytosis is a potential mechanism for 
cellular uptake. In order to probe the impact of endocytosis on the uptake of 
conventional pre-clinical and SDN formulations of efavirenz, a panel of 
endocytosis inhibitors was screened (Table 2). 
 
 
Figure 5 shows the cellular accumulation ratios generated for efavirenz (A) and SDN efavirenz 
(B). Also shown are the cellular accumulation ratio in the presence of dynasore, indomethacin 
and cytochalasin B. Data points indicate mean (± SD). 
 
The screen of endocytosis inhibitors demonstrated no effect on the accumulation 
ratio of either the pre-clinical formulation (CAR 92.65 ±47.41) or SDN 
formulation (CAR 118.7 ±40.98) of efavirenz when in the presence of dynasore 
(efavirenz CAR 96.74 ±13.14, P = 0.874, SDN CAR 121.8 ±17.99, P = 0.895), 
indomethacin (efavirenz CAR 137.6 ±60.04, P = 0.285, SDN CAR 119.4 ±16.5, 
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P = 0.975) or cytochalasin B (efavirenz CAR 96.53 ±47.18, P = 0.911, SDN 
CAR 141.4 ±35.44, P = 0.434).  
 
5.3.4 The Effects of Inhibitors of Endocytosis on Nanoparticle 
Uptake 
The addition of the DiD fluorescent dye was used as a marker for SDN uptake in 
order to determine the effects of endocytosis inhibitors on not only efavirenz 
uptake but also SDN uptake. The uptake of DiD labeled SDN efavirenz particles 
(4.02 ±0.86 relative fluorescence units [RFU]) were significantly reduced (Figure 
6) by dynasore (0.918 ±0.45 RFU, P = 0.001). Indomethacin had no effect on 
uptake of DiD labeled SDN efavirenz particles (3.44 ±0.58 RFU, P = 0.307), 
whereas cytochalasin B significantly increased uptake (5.40 ±0.70 RFU, P = 
0.048) (Figure 7).  
 
The uptake of dissolved DiD labeled SDN efavirenz particles (8.75 ±1.14 RFU) 
was significantly reduced by dynasore (0.43 ±0.13 RFU, P = <0.0001) and 
indomethacin (4.45 ±0.54 RFU, P = <0.000). Cytochalasin B significantly 
increased the uptake of dissolved DiD labeled SDN efavirenz particles (12.12 
±0.20 RFU, P = <0.001) (Figure 7). 
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Figure 6 shows a scatter plot of the fluorescence detected at 655-730 nm. The green plot 
represents untreated cells (A-D). The red plot represents cells treated with SDN DiD (A-D). The 
blue plot represents the fluorescence in the presence of dynasore (B), indomethacin (C) and 
cytochalasin B (D). 
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Figure 7 shows the fluorescence produced by cells treated with SDN DiD efavirenz (A) and 
dissolved SDN DiD efavirenz (B) in the presence of dynasore, indomethacin and cytochalasin B. 
Data points indicate mean (± SD). 
 
 132 
5.4 Discussion 
The data presented here demonstrated cellular accumulation of efavirenz was 
reduced significantly by montelukast and amantadine, with the reduction in 
accumulation by prazosin bordering on significance. Montelukast and prazosin 
have been previously shown to inhibit efavirenz accumulation in vitro; indicating 
one of the SLCO transporters may also be involved in the accumulation of 
efavirenz (157, 176). However, previous data demonstrated no interaction 
between efavirenz and SLCO1A2, SLCO1B1 or SLCO1B3 indicating a role of 
other transporters inhibited by montelukast (159, 160). The data also indicated 
the SDN formulation may interact with verapamil, probenecid, prazosin and 
montelukast. However, these data may be compromised due to low accumulation 
of the control in this experiment. The SDN formulation procedure generates 
particles in the size range of 322 ± 29nm. As described in section 5.1, particles of 
this size activate endocytosis and nanoformulation has been used previously to 
reduce the impact of the transporter, BCRP on drug uptake (161, 163). Further 
studies are required to fully elucidate the interactions of both the conventional 
pre-clinical and SDN formulations of efavirenz. 
 
The experiments utilising the endocytosis inhibitors provided some conflicting 
data. When the drug accumulation ratio was examined, the endocytosis inhibitors 
had no effect on either the pre-clinical conventional formulation or the SDN 
formulation of efavirenz. Interestingly, uptake of the DiD labelled SDNs was 
reduced by dynasore, indicating a role for dynamin-mediated uptake. However, 
the uptake of the dissolved DiD labelled SDNs was also reduced by both 
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dynasore and indomethacin. This may indicate the incomplete dissolution of the 
SDN particles, or that the dissolution process altered the structure of the SDN 
particles, enabling uptake via calveoli-dependent endocytosis. The data also 
demonstrated higher uptake for the dissolved DiD SDN particles. This is not 
entirely unexpected, as DiD is a lypophilic dye and would be expected to readily 
pass through the lipid cell wall. This limitation could be resolved by use of a cell 
impermeable dye, such as propidium iodide (fluorescence only observed when 
associated with intracellular nucleic acids). Propidium iodide has previously 
been incorporated into rhodamine B isothiocyanate–labeled silica nanoparticles 
to indicate cellular uptake (177). These data indicate the importance of 
measuring both nanoparticle uptake and drug uptake. Although the drug 
concentrations may be equal in both formulations, the mechanism of cell entry 
and consequently intracellular fate may be significantly different.  
 
The hCMEC/D3 cell line has been demonstrated to express many of the proteins 
found in the enterocytes of the BBB, making this cell line a suitable model for 
probing interactions at the BBB (178). One of the limitations of the hCMEC/D3 
cell line, is the incomplete formation of tight junctions (179). The BBB is 
characterised by the presence of tight junctions, limiting paracellular transport. In 
order to fully replicate the presence of tight junctions, the hCMEC/D3 cell line 
require technically demanding and prohibitively expensive culture conditions. It 
has been demonstrated to reproduce the tight junctions observed in vivo, sheer 
stress induced by a pulsatile flow was required (180). Therefore, although 
accumulation experiments are useful for identifying potential mechanisms of 
uptake at the BBB, they do not demonstrate permeability across the BBB.  
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One of the limitations of investigating transporter interactions in cell lines, is the 
lack of specificity in pharmacological transport inhibitors. For example Ko143 
was thought to be a specific inhibitor for BCRP. However, recently it has been 
demonstrated that Ko143 also inhibits ABCB1 and ABCC1 (181). Lack of 
specificity is also a consideration when examining inhibitors of endocytosis 
(182). In addition to other mechanisms of endocytosis, endocytosis inhibitors 
have also been shown to influence transport proteins, such as inhibition of 
ABCC1 by indomethacin (166). Furthermore, cytochalasin B was shown to 
disrupt actin filaments and increase the intracellular accumulation of doxorubicin 
via this mechanism. The authors concluded that organisation of actin filaments 
may play a role in the function of P-gp (183). The conclusions that are drawn 
here are based on the known interactions of the inhibitors used. It is possible that 
the transport inhibitors may inhibit other as yet unidentified transporters. Further 
studies utilising more specific methods (such as knock-down models, small 
interfering RNA and oocyte uptake experiments) may be utilised in future studies 
to further elucidate the interactions of efavirenz and transporters.  
 
Another limitation of the experimental design was that all experiments were 
conducted at 1 hour. This snapshot may not fully represent the mechanisms of 
uptake. Liptrott et al demonstrated that the cellular accumulation ratio of SDN 
efavirenz varied over 24 hours in THP-1 cells, with highest accumulation 
achieved within the first hour (184). Repetition of the experiments conducted in 
this chapter over multiple time points may provide further insight into the 
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mechanisms of uptake of the conventional pre-clinical and SDN formulations of 
efavirenz. 
The data presented in this chapter indicate that SDN formulated efavirenz may 
not traverse the BBB via the same mechanisms as the conventional formulation. 
Amantadine significantly reduced efavirenz uptake, while there was no effect 
observed with the SDN formulation. Additionally, dynasore reduced the uptake 
of SDN DiD labelled particles indicating a role of dynamin-mediated 
endocytosis. Differential mechanisms of uptake by the BBB may impact on the 
occurrence of CNS toxicity associated with efavirenz. 
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Chapter 6 
 
Efavirenz is predicted to accumulate in brain tissue: an in silico, 
in vitro and in vivo investigation 
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6.1 Introduction 
 
Despite its widespread use, patients receiving efavirenz-containing therapy 
frequently report CNS disturbances. Symptoms of efavirenz-associated adverse 
drug reactions (ADRs) occur with a high frequency and can include depression, 
anxiety, abnormal dreams and hallucinations (65). The majority of patients report 
development of CNS disorders shortly after commencing efavirenz therapy with 
symptoms dissipating during the initial months of therapy. A minority of patients 
continue to experience symptoms for the duration of efavirenz use (66). More 
recently, efavirenz CNS ADRs have been shown to have more long-term effects 
(67). 
 
In addition to the negative impact on the quality of the patient’s life, CNS ADRs 
may also lead to a decrease in patient adherence. Poor patient adherence to 
antiretroviral medication is a major concern with regards to HIV therapy, in 
particular drugs displaying a low genetic barrier to resistance such as efavirenz 
(185). The impact of CNS side effects on patient adherence is not clearly 
defined. Some previous studies indicate that patients demonstrate tolerance to 
CNS side effects with minimal impact on patient adherence (69, 70). However, a 
recent study demonstrated 60% of patients reported CNS side effects as the 
primary reason for discontinuation vs. 3% of patients receiving alternative 
antiretroviral therapies (67). 
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There is a paucity of information regarding penetration of efavirenz into brain 
tissue. Due to impracticalities in obtaining brain tissue from patients, some 
groups have used concentrations in cerebrospinal fluid CSF as a surrogate for 
brain concentrations. The majority of pharmacokinetic studies have focused on 
describing efavirenz plasma concentrations and elucidating genetic factors that 
contribute to the variability in efavirenz pharmacokinetics or genetic associations 
to predict patients at risk of developing CNS toxicity (65, 72, 74). However there 
are a few small studies that investigated efavirenz pharmacokinetics in both 
plasma and CSF. CSF concentrations have been shown to be much lower (around 
0.5%) than plasma. However, even at 0.5% of the plasma concentration efavirenz 
concentrations in the CSF exceed the IC50 of efavirenz for wild type HIV (57).  
 
The appropriateness of CSF concentrations as a surrogate for brain 
concentrations is currently the subject of debate (54-56). It has been 
demonstrated in guinea pigs that brain tissue concentrations of nevirapine not 
only differ from those in the CSF but also vary between brain regions (54). 
nevirapine uptake was shown to be 0.32 ml/g in the CSF whereas nevirapine 
uptake was lower in the choroid plexus (0.25 ml/g) and higher in the pituitary 
(1.61 ml/g) when compared to the CSF (54). Indeed, concentrations within CSF 
have been shown to vary depending on where the sample was taken for other 
antiretroviral drugs. Lamivudine has been shown to be 5-fold higher in CSF 
sampled from the lumbar region compared to ventricular CSF in rhesus monkeys 
(55). Although there are no comparable data for efavirenz in the literature, these 
data exemplify the challenges associated with predicting brain tissue 
concentrations in CSF. 
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PBPK modelling is a bottom up approach to simulate drug distribution in virtual 
patients. The approach mathematically describes physiological and molecular 
processes defining pharmacokinetics, integrating drug-specific properties (such 
as logP, Caco-2 apparent permeability and affinity for transporters and metabolic 
enzymes) and patient-specific factors (such as height, weight, gender, organ 
volumes and blood flow) (104). The model presented here is based on a full body 
PBPK model, supplemented with a 6-compartment model of the CNS and CSF 
as previously described (186). 
 
The aim of this investigation was to evaluate efavirenz penetration into the CSF 
and brain using PBPK modelling. Simulated efavirenz pharmacokinetic data 
were then compared to available experimental data from rodents and clinical data 
from humans. 
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6.2 Materials & Methods 
 
6.2.1 Materials 
Male Wistar rats were purchased from Charles River (Oxford, UK). Efavirenz 
powder (>98% pure) was purchased from LGM Pharma Inc (Boca Raton, USA). 
All other consumables were purchased from Sigma Aldrich (Dorset, UK). 
 
6.2.2 Animals and treatment 
Male Wistar rats (Charles River UK) weighing 180 – 220 g on arrival were used 
for pharmacokinetic analysis of efavirenz. Food and water were provided ad 
libitum. All animal work was conducted in accordance with the Animals 
(Scientific Procedures) Act 1986 (ASPA), implemented by the United Kingdom 
Home Office.  
  
6.2.3 Drug Treatment 
Eight male Wistar rats were dosed with efavirenz (10 mg/kg, 2 ml/kg 0.5% 
methylcellulose in dH2O) based on individual weight taken prior to dosing. 
Dosing was administered once daily via oral gavage over 5 weeks. The animals 
were terminated 2 hours after the final dose and blood was collected via cardiac 
puncture. Blood samples were centrifuged at 2000g for 10 minutes at 4°C to 
separate plasma. Plasma was immediately frozen at -80°C and stored for later 
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analysis. Brain tissue was also collected and immediately stored at -30°C for 
analysis. 
 
6.2.4 Rapid Equilibrium Dialysis 
The protein binding of efavirenz in brain tissue was performed using rapid 
equilibrium dialysis (RED) as described by Liu et al. (150). Rat brain tissue was 
homogenised in 2 volumes (W:V) of 1% saline solution. Since efavirenz is 
highly protein bound, a dilution of brain tissue (10% and 20% brain tissue were 
prepared with 1% PBS) was used. 200 µl of brain homogenate was spiked with 
5000 ng/ml efavirenz and added to the donor chamber. The receiver chamber 
contained 350 µl of Sorensons buffer. The RED plate (Thermo, UK) was then 
placed in a shaking incubator for 4 hours at 37°C at 100 rpm. 250 µl were 
removed from the receiver chamber and frozen at -80°C for analysis. The 
fraction of drug unbound (fu) in brain tissue was then calculated from the diluted 
brain tissue using the following formula (187): 
 
𝑈𝑛𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑓𝑢 = 1𝐷1𝑓𝑢 𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 − 1 + 1𝐷  
 
Where fu = fraction unbound and D = dilution factor. 
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6.2.5 Sample preparation for bioanalysis 
Efavirenz was extracted by protein precipitation. 20µl of IS (lopinavir 
1000ng/ml) was added to 100µl of sample, standard or QC which was then 
treated with 400µl of ACN. Samples were then centrifuged at 4000g for 10 
minutes at 4°C. The supernatant fraction was transferred to a fresh glass vial and 
evaporated, samples were placed in a rotary vacuum centrifuge at 30°C and then 
reconstituted in 140 µl of H2O:ACN (60:40). 100µl of the sample was then 
transferred into 200µl chromatography vials. 5µl of each sample was injected for 
analysis by LC-MS/MS.  
 
Rat brain tissue was homogenised in 3 volumes (W:V) of plasma for 1 minute at 
maximum power using a Minilys® homogeniser (Bertin technologies, FR). 
Extraction was performed using protein precipitation detailed in the previous 
section. Recovery was tested at 3 levels (400 ng/ml 100 ng/ml and 20 ng/ml). 
Mean recovery was 95% (SD 8.9) and 91% (SD 7.8) for plasma and brain, 
respectively. Samples generated from the RED experiment were pre-treated with 
20% ACN (PBS and Sorensons buffer were spiked with 20% ACN in order to 
aid efavirenz solubility in these matrices) and mean recovery was 84% (SD 
11.6). 
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6.2.6 Quantification of Efavirenz 
Quantification of efavirenz was achieved utilising the validated LC-MS/MS 
method described in chapter 4.  
 
6.2.7 PBPK Parameters 
The full body PBPK model used here has been previously published using 
equations from the physB model (Figure 1) (104, 106). The model generates 
virtual patients based on a statistical description of human anatomy. The model 
simulates flow rates, organ volumes and other tissue volumes based on 
anthropometric measures and allometric scaling.  
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Figure 1 shows a diagram of the full body PBPK model generated from the physB equations.  
 
Briefly, the equations required to simulate factors such as volume of distribution 
were previously published. Volume of distribution was simulated using the 
Poulin and Theil equation (188). This method describes the tissue to plasma ratio 
based on the individual organ volumes generated from the physB equations. 
Clearance was calculated using allometric scaling of metabolism of efavirenz in 
microsomes and accounting for activity and abundance of CYP2B6, CYP2A6, 
CYP1A2, CYP3A4 and CYP3A5, and UGT2B7. Physicochemical properties of 
efavirenz data (including log P, molecular weight, pKa) and in vitro data 
(permeation across Caco-2 cells and protein binding) were gathered from the 
literature and incorporated into the full body model (105). 
 
Heart
Lungs
Brain
Venous	flow
Muscle
Kidney
Ar
te
ria
l	F
lo
w
Gut
Pancreas
Spleen
Bones
Skin
Adipose
Liver
Simulated	
Oral	Dose
 146 
The CNS portion of the model was based on validated parameters describing 
CNS and CSF physiology and anatomy (186). A schematic of this model is 
shown in Figure 2. Physiological and physicochemical properties used are 
displayed in Table 1.  
 
 
Figure 2 shows a diagram of the CNS component of the PBPK model to describe efavirenz 
movement within the CNS.  
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Model Parameter Value Reference 
 
Molecular Weight 
LogP 
pKa 
Caco-2 permiability  
(10-6 cm/s) 
 
Fraction unbound 
Plasma 
CSF 
Brain tissue 
 
Qcsf (ml/min) 
Qecf (ml/min) 
 
315.7 
4.6 
10.2 
2.5  
 
 
 
0.01 
0.238 
0.00197 
 
0.175  
0.4 
 
Siccardi et al, (105) 
Siccardi et al, (105) 
Siccardi et al, (105) 
Siccardi et al, (105) 
 
 
 
Almond et al, (189) 
Avery et al, (190) 
 
 
Westerhout et al, (186) 
Westerhout et al, (186) 
Brain ICS (ml) 
Brain ECF (ml) 
CSF LV (ml) 
960  
240 
22.5 
Westerhout et al, (186) 
Westerhout et al, (186) 
Westerhout et al, (186) 
CSF TFV (ml) 22.5 Westerhout et al, (186) 
CSF CM (ml) 7.5 Westerhout et al, (186) 
CSF SAS (ml) 90 Westerhout et al, (186) 
 
Table 1 shows the physiological and physicochemical variables used to generate the PBPK 
model. 
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The equations used in the model presented here are as follows: 
 
1. 𝑙𝑜𝑔𝑃𝑆 =  −2.19 + 0.262 𝑙𝑜𝑔𝐷 + 0.0583 𝑣𝑎𝑠!"#$ − 0.00897 𝑇𝑃𝑆𝐴	
 
Equation 1 shows a 3-descriptor QSAR (quantitative structure–activity 
relationship) model of permeability surface area product (log PS) of the 
developed by Liu et al. (191). The three descriptors are log D (octanol/water 
partition coefficient at pH 7.4), vasbase (van der Waals surface area of the basic 
atoms) and TPSA (van der Waals polar surface area). Permeability surface area 
product of the blood CSF barrier (pse) was calculated by dividing the 
permeability surface area product of the BBB (psb) by 1000, to reflect the 
smaller surface area of the blood CSF barrier (192). 
 
2. ∆!"#!"∆! = 𝑝𝑠𝑏 ∗ !"#!"∗!"! − 𝐸𝐹𝑉!" ∗ 𝑓𝑢!" − 𝑄!"# ∗ 𝐸𝐹𝑉!" ∗ 𝑓𝑢!" 	
 
Equation 2 describes the movement of efavirenz from arterial plasma to the brain 
where concentration of arterial efavirenz (efavirenzAr), fraction unbound in 
plasma (fu), blood to plasma ratio (R), concentration of efavirenz in the brain 
(efavirenzBr), flow of brain extracellular fluid (Qecf), and fraction unbound in 
brain and (fuBr). 
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3. ∆!"#!"# !"∆! = 𝑝𝑠𝑒 ∗ !"#!"∗!"! − 𝑝𝑠𝑒 ∗ 𝐸𝐹𝑉!" ∗ 𝑓𝑢!"# − 𝑄!"# ∗ 𝐸𝐹𝑉!" ∗𝑓𝑢!! − 𝑄!"# ∗ 𝐸𝐹𝑉!" 		4. ∆!"#!"# !"#∆! = 𝑝𝑠𝑒 ∗ !"#!"∗!"! − 𝑝𝑠𝑒 ∗ 𝐸𝐹𝑉!"# ∗ 𝑓𝑢!"# − 𝑄!"# ∗ 𝐸𝐹𝑉!" −𝑄!"# ∗ 𝐸𝐹𝑉!"# 		5. ∆!"#!"# !"∆! = 𝑝𝑠𝑒 ∗ !"#!"∗!"! − 𝑝𝑠𝑒 ∗ 𝐸𝐹𝑉!" ∗ 𝑓𝑢!"# − 𝑄!"# ∗ 𝐸𝐹𝑉!"# −𝑄!"# ∗ 𝐸𝐹𝑉!" 	
 
6. ∆!"#!"# !"!∆! = 𝑄!"# ∗ 𝐸𝐹𝑉!" − 𝑄!"# ∗ 𝐸𝐹𝑉!"!	
 
Equations 3 to 6 describe the movement of efavirenz from the brain to CSF, 
including movement across the blood CSF barrier. The CSF is subdivided into 4 
compartments left ventricle (LV), third and fourth ventricle (TFV), cisterna 
magna (CM) and the subarachnoid space (SAS) where concentration of efavirenz 
in veins (efavirenzVe), fraction unbound in plasma (fu), blood to plasma ratio (R), 
concentration of efavirenz in the brain (efavirenzBr), concentration of efavirenz in 
the CSF compartments (efavirenzCSF), flow of brain extracellular fluid (Qecf), 
flow of CSF (Qcsf) fraction unbound in CSF (fuCSF) and fraction unbound in brain 
and (fuBr). 
 
 
 
 150 
6.2.8 Simulation Design 
A virtual cohort of 100 patients of ages 18 to 60 were generated and a once-daily 
dose of efavirenz (600 mg) was simulated over 5 weeks. Physiological 
parameters (such as weight, height and body mass index) were described be 
Bosgra et al (104). The physiological values were the used to generate organ 
volumes via allometric scaling. Simulations were conducted using SimBiology 
v4.3.1 (a module of Matlab v8.2). The pharmacokinetics in plasma, CSF and 
brain tissue were recorded during the final 24 hours at steady state. Plasma and 
CSF pharmacokinetic simulations were compared with previous data generated 
from clinical trials. Brain tissue to plasma ratios were also calculated and 
compared to data generated in rodents. 
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6.3 Results 
The protein binding of efavirenz in brain tissue was determined using rapid 
equilibrium dialysis. The mean (± SD) concentration of efavirenz detected in the 
receiver chamber was 209.7 ± 33.4 ng/ml, and 165 ± 22.0 ng/ml 10% and 20% 
brain homogenate respectively. The fraction unbound in brain tissue (fuBr) was 
calculated to be 0.00181 and 0.00212 in 10% and 20% brain homogenate, 
respectively. The average fuBr was 0.00197. 
 
Following 5 weeks of oral dosing of efavirenz (10 mg/kg), the median plasma 
concentration of efavirenz in rats was 69.7 ng/ml (IQR 44.9 – 130.6). Median 
efavirenz concentrations in brain tissue were 702.9 ng/ml (IQR 475.5 – 1018.0). 
The median tissue to plasma ratio was 9.5 (IQR 7.0 – 10.9). 
 
6.3.1 Simulation 
A standard dosing schedule of efavirenz (600 mg once daily) was simulated in 
100 patients for the duration of 5 weeks. The results for efavirenz concentrations 
in plasma (Figure 3A), CSF (Figure 3B) and brain tissue (Figure 3C) were all 
taken from the final 24 hours of the simulation. 
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The maximum concentration (Cmax), minimum concentration (Cmin) and area 
under the curve (AUC24) of efavirenz in plasma were 3184 ng/ml (IQR 2219-
4851), 2537 ng/ml (IQR 1942-3779) and 76,991 ng.h/ml (IQR 62,170-107,560). 
The CSF was predicted to have lower concentrations of efavirenz Cmax 51.0 
ng/ml (IQR 38.3-70.0), Cmin 47.8 ng/ml (IQR 36.1-66.7) and AUC24 1193 
ng.h/ml (IQR 898-1649). At 24 hours efavirenz in the CSF was 1.6% of plasma 
concentrations. The simulation predicted efavirenz concentrations in the brain to 
exceed CSF and plasma, Cmax 50,343 ng/ml (IQR 38351-65799) Cmin 49,566 
ng/ml (IQR 38044-64374) and AUC24 1,207,542 ng.h/ml (IQR 926,900-
1,567,974).  The brain tissue to plasma partition ratio at 24 hours was 15.8.  
 
The absorption constant (Ka) was predicted to be 0.19 h-1 (IQR, 0.18-0.21). 
Volume of distribution (VSS) and clearance (Cl) were predicted to be 2.15 l/kg 
(IQR 2.06-2.31) 4.56 l/h (IQR 3.52-5.33) respectively. The fraction absorbed (fa) 
of efavirenz was predicted to be median 0.46 (IQR, 0.44-0.49) and was used to 
calculate apparent VSS and apparent Cl, 323.31 l (IQR 308.31-346.28) and 9.79 
l/h (7.54-11.41) respectively. 
 
6.3.2 Comparison with clinical data 
The simulated pharmacokinetic parameters in plasma produced by the model 
were in agreement with data published from human trials and population 
pharmacokinetic studies (popPK). Table 2 shows the results from the simulation 
and a number of clinical studies and popPK studies. The mean/median observed 
plasma concentrations of efavirenz ranged from 1973 ng/ml to 3180 ng/ml (57, 
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148, 193-195).  Simulated Cl, VSS and Ka were 1.04 fold, 1.28 fold and 0.6 fold 
different compared to observed data (195). The average simulated CSF 
concentrations were 49.9 ng/ml (IQR 36.6-69.7) compared to a range of 11.1 
ng/ml to 16.3 ng/ml observed in previously published clinical studies (57, 193). It 
is worth considering that the CSF concentrations were gathered from relatively 
small cohorts (Best N=80, Yilmaz N=1 and Tashima N=10) and may not fully 
represent CSF concentrations larger populations. Currently there are no clinical 
data describing the concentrations of efavirenz in human brain tissue.
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6.4 Discussion  
The data presented here show that the PBPK model predicts efavirenz to 
accumulate in the brain. This is to a higher degree than concentrations in the 
CSF, indeed concentrations of efavirenz in the brain were predicted to exceed 
even plasma concentrations, with a brain to plasma ratio of 15.8. The rodent data 
presented here supports the model prediction of a higher concentration of 
efavirenz in brain tissue, with a median tissue to plasma ratio of 9.5. Recently, 
efavirenz has been demonstrated to accumulate in the brain tissue of macaques. 
Following 8 days of orally administered efavirenz (60 mg/kg) the concentrations 
in plasma and CSF were 541 and 3.30 ng/ml respectively. Concentrations of 
efavirenz in the cerebellum and basal ganglion were 6.86 µg/g (tissue to plasma 
ratio 12.7) and 2.01 µg/g (tissue to plasma ratio 3.7), respectively (149).  
 
Accumulation of efavirenz in brain tissue may be driven by physicochemical 
properties of efavirenz, in particular lipophilicity. Since efavirenz is a highly 
lipophilic compound (logP 4.6) and has high accumulation in multiple cell types, 
it shows high cellular permeation (105). The brain has been shown to have a high 
fat content, with approximately 60% of the brain consisting of fat, providing a 
lipophilic environment for efavirenz (196). An additional factor that favours 
penetration is the high degree of protein binding of efavirenz. In plasma, 
efavirenz is highly protein bound (fu 0.01) (189). Protein binding in the CSF is 
much lower leading to more free efavirenz, fu 0.238 (190).  The data presented 
here from rapid equilibrium dialysis shows efavirenz fu in rodent brain tissue to 
be 0.00197. Further experimentation is required to define the factors determining 
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efavirenz accumulation in the CNS however, further in silico experiments may 
also identify important factors. By performing sensitivity analyses on each of the 
model parameters (e.g. fuBr, blood brain barrier permeability and blood CSF 
barrier permeability), simulations can be designed to identify the impact of each 
factors identifying which variables have the greatest influence on efavirenz CNS 
accumulation. Taken collectively, it is tempting to speculate that a combination 
of low fu and affinity for the lipophilic environment of the brain result in 
accumulation of efavirenz in the CNS. Lypophilicity has been shown to be a 
significant factor in uptake of drugs into the brain (51) as has been demonstrated 
with benzodiazepines. Lypophilicity, but not plasma protein binding, was shown 
to correlate with uptake of benzodiazepines into the brain. However, this study 
did not consider fu in the brain and plasma fu may not be a good indicator of 
brain fu. Kalvass et al examined the fu in plasma and brain tissue of 34 drugs 
covering multiple drug classes. The data presented showed that plasma fu both 
under and overestimated brain fu depending on the drug (197). 
 
Although this is the first study to employ PBPK modelling to investigate 
efavirenz penetration into the CNS, PBPK has been used previously to 
investigate efavirenz dose optimisation, drug-drug interactions and 
pharmacokinetics in special populations (105, 198). 
 
Limitations of this work include that the presented model does not take into 
account genetic variability (i.e. CYP2B6 variants), the brain fu values were 
generated in rodent brain rather than human brain, the current model is not able 
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to estimate local concentrations in individual brain regions, and permeability of 
efavirenz was calculated using a QSAR model of passive permeability which 
often rely on extrapolated data from animals with important differences to 
humans (191, 199). However, these aspects could be expanded in future 
modelling strategies as the necessary input data emerges.  
 
The BBB is highly effective at preventing xenobiotics penetrating the CNS. 
Tight cellular junctions prevent paracellular transport of drugs and the 
metabolising enzymes and transport proteins remove drugs from the CNS. As 
such, another potential limitation of the model that warrants further elaboration is 
that penetration of efavirenz across the BBB may not be governed purely by 
passive permeability. The potential influence of influx and efflux transporters 
was not considered because efavirenz is not classified as substrate of any 
transporters and effects of transporters on efavirenz pharmacokinetics have not 
been described. The model presented here potentially may be improved upon in 
the future if efavirenz is demonstrated to be a substrate for such transporters.  
 
There are numerous studies demonstrating that efavirenz plasma concentrations 
are associated with the development of CNS toxicity. Additionally, there are a 
number of studies showing efavirenz readily passes the BBB and is present in 
CSF. However, both plasma and CSF concentrations indicate that efavirenz is 
present in brain tissue, the site of CNS ADRs. The simulations presented here 
indicate both plasma and CSF may underestimate efavirenz exposure within the 
brain. Limitations associated with obtaining tissue biopsies and paired plasma 
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and CSF samples from patients make PBPK modelling an attractive tool for 
estimating such drug distribution. 
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Chapter 7 
 
General Discussion 
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Currently, the WHO recommends global treatment of HIV should consist of 1 
NNRTI supported by an NRTI backbone (64). The most frequent combination 
administered is efavirenz, co-administered with tenofovir and emtricitabine. This 
combination is co-formulated into a single tablet (Atripla), which is administered 
once daily (26).  
 
Patients receiving efavirenz-containing therapy frequently report CNS 
disturbances. Symptoms occur with a high frequency and can include depression, 
anxiety, abnormal dreams and hallucinations (65). The majority of patients report 
development of CNS disorders shortly after commencing efavirenz, with 
symptoms dissipating during the initial months of therapy. A minority of patients 
continue to experience symptoms for the duration of efavirenz-containing 
therapy (66). More recently however, efavirenz CNS toxicities have been shown 
to have more long-term (as discussed in section 1.4.1) (67). The mechanisms of 
efavirenz-associated CNS toxicity are complex and multifactorial. The 
difficulties in determining the underlying mechanisms of CNS toxicity are 
further compounded by the paucity of information detailing the distribution of 
efavirenz in the CNS. 
 
The aims of this thesis were firstly to investigate the underlying mechanism of 
efavirenz CNS toxicity, and secondly to assess uptake and CNS toxicity of 
efavirenz and a novel SDN formulation of efavirenz. To investigate the 
mechanisms of efavirenz-associated CNS toxicity, a cohort of patients were 
assessed for the association of efavirenz discontinuation and polymorphisms in 
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the GABAa receptor (chapter 2). Currently, it is not understood how efavirenz 
enters or is restricted from the CNS. To investigate the mechanisms, a panel of 
transport inhibitors were screened using the hCMEC/D3 cell line (chapter 5). 
While plasma and CSF concentrations are published, there is no data on human 
brain tissue concentrations. Given the importance of the CNS in efavirenz 
therapy (both as a site of continued HIV replication and CNS side effects), its 
penetration into the CNS has not been fully characterised. Given the obvious 
difficulties of obtaining brain tissue samples, PBPK modelling coupled with in 
vitro and in vivo techniques were utilised to simulate efavirenz distribution in the 
CNS (chapter 6). 
 
The interactions of a novel SDN formulation with the CNS were also 
investigated. As the underlying mechanisms of efavirenz-associated CNS 
toxicity are currently unknown, the effect of SDN formulation on the occurrence 
of neurocognitive disturbances was assessed in a rodent model of anxiogenesis 
(chapter 3). As with efavirenz, the mechanisms of uptake of SDNs into the CNS 
are currently unknown. To investigate the mechanisms of uptake, a panel of 
transport and endocytosis inhibitors were screened using the hCMEC/D3 cell 
line (chapter 5). In order to quantify efavirenz in multiple matrices examined in 
this thesis, a robust bioanalytical method was required (chapter 4).  
 
Despite being available for prescription for almost 20 years, the underlying 
mechanisms of CNS toxicities associated with efavirenz are still poorly 
characterised (26). One of the aims of this thesis was to investigate the role of the 
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GABAa receptor in the occurrence of efavirenz CNS toxicity. Despite in silico 
evidence (produced during a previous masters course) and in vitro data 
(published by Gatch et al), the genotyping of patients failed to support a role of 
the GABAa receptor (127). As discussed in chapter 2, this may be due to 
limitations of the study design, or indeed the GABAa receptor playing no part in 
the aetiology of efavirenz-associated CNS toxicities. The approach used in 
chapter 2 may not have been optimal in identifying genetic associations with the 
complex phenotype of efavirenz CNS toxicity. The symptoms observed in 
efavirenz associated CNS disturbances are potentially due to interactions with 
multiple receptors. SNPs in a single receptor would need to be very strongly 
associated with the occurrence of CNS toxicity to be detected by the selection of 
SNPs. An alternate approach that may be employed in future studies is haplotype 
tagged SNPs. This approach allows detection of variation in not only candidate 
genes but also entire gene regions. This allows the examination of larger regions, 
increasing the potential to identify genetic associations (200). The data presented 
in this thesis could be built upon with further in vitro mechanistic and genetic 
studies examining the many isoforms of the GABAa receptor but this was 
beyond the scope of the current analysis (111). 
 
Another source of inter-patient variability may be due to the mechanisms of 
efavirenz entry into the CNS. The data presented in chapter 5 indicates efavirenz 
may be a substrate for OCT1 and possibly one of the SLCO transporters. If these 
interactions are confirmed via further in vitro experimentation, genotyping for 
polymorphisms may contribute to explaining the variation in occurrence of 
efavirenz CNS toxicity. Additionally, if these interactions are confirmed and 
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fully characterised (determination of maximum velocity [Vmax] and Michaelis 
constant [Km]), they could be used to improve the PBPK model in chapter 6. 
The current model is forced to assume passive permeation, due to incomplete 
characterisation of efavirenz interactions with transporters. PBPK modeling 
would offer the opportunity to assess the clinical relevance of any transporter 
interaction.  
 
Current human studies indicate that efavirenz shows moderate penetration into 
the CNS, determined by concentrations in CSF. Plasma concentrations of 
efavirenz have been shown to vary between 154- and 228-fold greater than those 
found in CSF (50, 57, 148). The data presented in this thesis demonstrates that 
CSF concentrations may underestimate the concentrations present in brain tissue, 
estimated to have a brain to plasma ratio of 15.8. The simulated data was 
supported by in vivo data indicating higher accumulation of efavirenz in the brain 
tissue (149). These data demonstrate the importance of considering the 
concentrations of efavirenz in brain tissue, particularly in the scope of CNS 
toxicity.  
 
The second aim of this thesis was to assess uptake and CNS toxicity of a novel 
SDN formulation of efavirenz. The data presented indicate the SDN formulation 
may induce anxiety to a lesser extent than the conventional pre-clinical 
formulation, whilst displaying superior in vivo pharmacokinetics (97). A 
significant disadvantage of this study was comparing pharmacokinetic data 
determined following a single dose to behavioural data generated at steady state. 
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In order to fully interpret these data, the pharmacokinetics must be assessed at 
steady state. These data, in conjunction with the data presented in chapter 5, 
indicate the SDN formulation of efavirenz may interact with the CNS via 
different mechanisms to the conventional pre-clinical formulation of efavirenz.  
 
Chapter 5 investigated the mechanisms of uptake of SDN formulated efavirenz in 
the hCMEC/D3 cell line. The screen of transport inhibitors indicated the cellular 
accumulation of the SDN formulation was reduced by verapamil, probenecid, 
prazosin and montelukast. These data indicate a potential interaction with 
multiple transporters. However, (as discussed in section 5.4) these data require 
repetition before any definitive conclusions may be drawn. The transport 
inhibitors also demonstrated no significant reduction in the CAR of SDN 
efavirenz in the presence of amantadine, which significantly reduced the CAR of 
the conventional pre-clinical formulation of efavirenz. These data indicate 
efavirenz may be a substrate of OCT 1 or 2 and SDN efavirenz may reduce the 
influence of this interaction. The screen of endocytosis inhibitors indicated that 
dynamin-mediated uptake may be important for particle uptake but the effect on 
intracellular drug concentrations is uncertain. Although the data indicated no 
significant difference in efavirenz intracellular concentrations, the mechanism of 
uptake may influence the intracellular fate of efavirenz. Further investigations 
could be planned to investigate the mechanisms of efavirenz uptake and 
determine the potential impact on systemic distribution and intracellular 
concentrations. 
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Although presented in isolation, the work conducted in this thesis forms part of 
an iterative process that connects drugs available for clinical usage and the 
generation on novel nanoformulations with bespoke behaviours (Figure 1). Once 
a need has been identified (in this case to overcome poor water solubility of 
efavirenz), a screen of potential nanoformulations can be generated to address 
this issue. The initial formulation process, described by McDonald et al, included 
a screen of 49 polymers and surfactants and characterisation of the properties of 
the resulting SDN formulations (97).  
 
Following generation of candidates, initial pharmacological assessment 
(including Caco-2 accumulation, cytotoxicity, transwell permeability, in vivo 
pharmacokinetics and PBPK simulation) lead to the generation of the SDN 
formulation used in this thesis (97). The work presented in this thesis examined 
the SDN efavirenz formulation in detail, examining potential interactions with 
the CNS (chapter 3 and 5). However, all the techniques in this thesis may be 
applied to the investigation of SDNs of other xenobiotics, or indeed other 
formulation techniques.  
 
Although the in vivo data generated in chapter 3 was specific for examining the 
CNS toxicity of efavirenz, other appropriate animal models may be used. For 
example, if nevirapine were to be formulated to produce SDNs, an animal model 
of hypersensitivity or hepatotoxicity may be more appropriate (201). The 
screening process detailed in chapter 5 could be adapted to focus on known 
transporter interactions (e.g. the interactions of lopinavir and transporters such as 
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P-gp and OATP1B1 are well characterised), or to examine other key anatomical 
areas of interest (e.g. testis, gut-associated lymphoid tissue and lymph nodes) 
(83, 202). The PBPK model presented in chapter 6 may be further refined to 
examine the distribution of SDN formulated efavirenz or indeed other novel 
formulations, offering the opportunity to predict the impact of various 
formulation strategies. The data generated at each of these steps may be used to 
further inform each of the other steps to lead to the further refinement and 
eventual clinical application of nanoformulated drugs. 
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To summarise, the data presented in this thesis failed to identify an association 
with efavirenz treatment discontinuation and polymorphism in the GABAa 
receptor. However, the evidence presented here is not strong enough to discount 
interactions with the GABAa receptor completely. Further investigation is 
required to identify potential interactions. This could be accomplished via in 
vitro assessment of activation or inhibition of the GABAa receptor by efavirenz 
(using expression of various isoforms of the GABAa receptor in cell lines or 
xenopus laevis oocytes followed by receptor electrophysiology experimentation). 
Chapter 3 demonstrated the potential of SDN formulation to reduce the impact of 
anxiogenesis in a rodent model. The key limitation that must be addressed in 
future studies is that the steady state pharmacokinetics were not assessed. 
Chapter 5 demonstrated efavirenz might be a substrate for OCT1 and one of the 
SLCO transporters. Further experimentation is required to confirm and 
characterise these potential interactions. Additionally, genetic studies may be 
employed to assess the clinical relevance of the interactions of efavirenz with 
transporters. Finally, chapter 6 demonstrated in vivo and in silico accumulation 
of efavirenz in brain tissue. The model presented in chapter 6 could be further 
modified (following the relevant in vitro, ex vivo and in vivo experimentation) to 
investigate the penetration of other drugs, not only into CSF, but also brain 
tissue. The data presented in this thesis may be built upon to understand the 
mechanisms governing efavirenz disposition in the CNS and factors influencing 
the occurrence of CNS toxicity. 
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